Podcasts about M0

Featuring perspectives from Dr Charles J Ryan and Ms Brenda Martone, including the following topics: Introduction (0:00) Case: A man in his late 60s with metastatic hormone-sensitive prostate cancer and high-volume disease burden — Brenda Martone, MSN, NP-BC, AOCNP (8:09) Case: A man in his early 70s with M0 prostate cancer and rising PSA on androgen deprivation therapy — Ms Martone (35:00) Case: A man in his early 70s with metastatic castration-resistant prostate cancer and a somatic BRCA2 mutation — Ms Martone (44:30) NCPD information and select publications

On this week's episode of Fanboys, the boys crank the suck, confront their pill addiction, and level up their MIDI stat. If you want to hear them verbally assault every band from 2004, grab the full episode on The Hard Times' Patreon! (https://patreon.com/thehardtimes) ALSO: are you in a shitty band? Want to hear the Fanboys try to say something nice about it? Submit your music to Edgar's Twitter (https://twitter.com/EdgarTowner)! Be sure to check out this week's featured artists: Law Abiding Citizens (https://lawabidingcitizensog.bandcamp.com/album/social-hackers-ep), Death to Slater (https://www.youtube.com/watch?v=M0-t-sX5twg), Im2LyriCal (https://open.spotify.com/album/0vnEdEJirS3xXieOy8uicK?highlight=spotify:track:1jaMtD0RQ9frKN4Qv5fNHd), ElPlasa (https://soundcloud.com/elplasa/birdhaven-battle-theme?utm_source=cards-frame.twitter.com&utm_campaign=wtshare&utm_medium=widget&utm_content=https%253A%252F%252Fsoundcloud.com%252Felplasa%252Fbirdhaven-battle-theme), Grouphal (https://grouphal.bandcamp.com/album/grouphal), and Nowhere Days (https://nowheredays.bandcamp.com/album/circling-the-drain) 

Proceedings from the fifth in a series of 11 integrated webinars held in association with the 2021 ONS Annual Congress. Featuring perspectives from Drs Charles J Ryan, A Oliver Sartor and Mary-Ellen Taplin on cases from the practices of Ms Kathy D Burns, Ms Brenda Martone and Mr Ronald Stein, including the following topics: Introduction (0:00) Case: A man in his late 50s with metastatic hormone-sensitive prostate cancer and high-volume disease burden — Ronald Stein, JD, MSN, NP-C, AOCNP (4:32) Case: A man in his early 70s with M0 prostate cancer and rising PSA on androgen deprivation therapy — Kathy D Burns, RN, MSN, AGACNP-BC, OCN (38:25) Case: A man in his early 70s with metastatic castration-resistant prostate cancer (mCRPC) and a somatic BRCA2 mutation — Brenda Martone, MSN, NP-BC, AOCNP (54:47) Case: A man in his late 60s with mCRPC, a somatic BRCA1 mutation and loss of heterozygosity — Mr Stein (1:15:59) NCPD information and select publications

This week's EYE ON NPI is easy-as-pie: it's the Raspberry Pi RP2040 microcontroller (https://www.digikey.com/en/products/detail/raspberry-pi/SC0908-7/14306009), finally available for purchase in tape and reel for manufacturing. The RP2040 is one of the most hotly-anticipated EYE ON NPI's of the year - it's been a few months since we've been enjoying the RP2040 in devboards. Adafruit has featured it in many popular dev boards like the QT Py RP2040 (https://www.adafruit.com/product/4900), Feather RP2040 (https://www.digikey.com/en/products/detail/adafruit-industries-llc/4884/14000603) and ItsyBitsy RP2040 https://www.digikey.com/en/products/detail/adafruit-industries-llc/4888/14115610). Thanks to the Raspberry Pi Foundation, Adafruit got a few early reels so we could develop our layouts and board designs - that whetted the appetites of a lot of developers who saw the massive number of designs available from Sparkfun, Pimoroni, Seeed and others and wanted to join in the fun! Well, now you can because Digi-Key is stocking the chips in reels for anyone to purchase. They're available in 7" reels (https://www.digikey.com/en/products/detail/raspberry-pi/SC0908-7/14306009) with 500 chips in a spool, or in 13" reels (https://www.digikey.com/en/products/detail/raspberry-pi/SC0908-13/14306010) with 3400 chips. At a cost of $1 each pre-quantity (quantity pricing is not yet determined) For that $1, you get a lot of technology: RP2040 Chip features: Dual ARM Cortex-M0+ @ 133MHz 264kB on-chip SRAM in six independent banks Support for up to 16MB of off-chip Flash memory via dedicated QSPI bus DMA controller Fully-connected AHB crossbar Interpolator and integer divider peripherals On-chip programmable LDO to generate core voltage 2 on-chip PLLs to generate USB and core clocks 30 GPIO pins, 4 of which can be used as analog inputs Peripherals 2 UARTs 2 SPI controllers 2 I2C controllers 16 PWM channels USB 1.1 controller and PHY, with host and device support 8 PIO state machines The RP2040 uses the Cortex M0+ core, which is is good for microcontroller projects. It's not fast enough or capable of running Linux like a Raspberry Pi computer but it can run Arduino/MicroPython/RTOS pretty easily. To make up for the M0 core, the chip is run very fast, at ~130MHz, much faster than many of the Cortex M0's we've worked with that tend to run at 48 Mhz or so. Since it is an M0 chip, it does not have a floating point unit or DSP hardware support - so if you're doing something with heavy floating point math, it will be done in software and thus not as fast as a Cortex M4. For peripherals, there are two I2C controllers, two SPI controllers, and two UARTs that are generously multiplexed across the GPIO - check the pinout for what pins can be set to which. There are 16 PWM channels, each pin has a channel it can be set to (ditto on the pinout). While its not a full crossbar-type chip, it's easy to find pins for your peripherals. You'll note there's no I2S peripheral, or SDIO, or camera, what's up with that? Well instead of having specific hardware support for serial-data-like peripherals like these, the RP2040 comes with the PIO state machine system which is a unique and powerful way to create custom hardware logic and data processing blocks that run on their own without taking up a CPU. For example, NeoPixels - often we bitbang the timing-specific protocol for these LEDs. For the RP2040, we instead use PIO object that reads in the data buffer and clocks out the right bitstream with perfect accuracy. Same with I2S audio in or out, LED matrix displays, 8-bit or SPI based TFTs, even VGA! In MicroPython and CircuitPython you can create PIO control commands to script the peripheral and load it in at runtime. There are 2 PIO peripherals with 4 state machines each. While the RP2040 has lots of onboard RAM (264KB), it does not have built-in FLASH memory. Instead, that is provided by the external QSPI flash chip. You will need to provide external FLASH memory using QSPI NOR memory. The flash chip is shared between the program it's running and any file storage used by MicroPython or CircuitPython. We like this GigaDevice chip (https://www.digikey.com/en/products/detail/gigadevice-semiconductor-hk-limited/GD25Q80CSIGR/9484688) but just about any QSPI flash memory will work just fine. You'll also need a 12 MHz crystal and lots of capacitors and some passive components to finish off the design. With top-notch documentation, lots of board examples, firmware-aplenty, and of course a rock-bottom price, its an excellent chip to use for just about anything. Especially with the PIO peripherals, this chip can 'punch up' quite a bit and perform tasks or process data that normally would require much more powerful chips or advanced peripherals - things like cameras, TFT displays, motor drivers, PDM/I2S/PCM encoding and more. Sign up to be notified the moment the RP2040 chips are in stock at Digi-key here (https://www.digikey.com/short/8mt22d38)

Venha saber mais sobre radioterapia hipofracionada ouvindo este episódio!O FAST-Forward é um estudo multicêntrico, de fase 3, randomizado, de não inferioridade realizado em 97 hospitais no Reino Unido. Pacientes com pelo menos 18 anos de idade e portadoras de carcinoma invasivo da mama (pT1–3, pN0–1, M0) eram randomizadas para esquemas de RT após cirurgia de conservação da mama ou mastectomia.Esquemas com 26 ou 27 Gy em 5 frações foi comparada com o esquema padrão de 40 Gy em 15 frações.Com o endpoint primário de recidiva do tumor de mama ipsilateral, este Estudo foi considerado positivo!Aprenda sobre conceitos em câncer de mama e um pouco desta história com Wesley Andrade e Rodrigo Hanriot. Sejam bem vindos ao Clinical Papers Podcast! Para saber mais sobre o paper, acesse: https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(20)30932-6/fulltext

Névnapok, születésnaposok, évfordulók említése után Lapszemle és Tőzsdei helyzetkép. BUDAPEST TE CSODÁS: Jön a vasúti M0-ás! Min változtathat? - Andó Gergely, a Közlekedésvilág lapcsoport lapigazgatója. ÉBRESZTŐ: A Nagy Csirkemell Blöff. Mégsem drágul annyira? - Raskó György agrárközgazdász. KKV ROVAT: Olcsó a vállalkozói hitel, viszik is mint a cukrot! E-COMMERCE: 4 cég 4 hír a fenntarthatóság jegyében - Palocsay Géza, a Jófogás és a Használtautó.hu ügyvezető igazgatója

Prostate Cancer Update, Issue 2, 2021 — Part 1: Our interview with Dr Ryan highlights the following topics as well as cases from his practice: Practical factors influencing the selection of therapy for patients with nonmetastatic castration-resistant prostate cancer (nmCRPC) and metastatic hormone-sensitive prostate cancer (mHSPC) (0:00) Case: A man in his late 60s with nmCRPC receives first-line therapy with abiraterone (29:53) Case: A man with CRPC and high microsatellite instability attains a dramatic response to pembrolizumab (37:31) Perspective on the use of adjuvant radiation and salvage radiation therapy for patients with prostate cancer (46:10) PSMA (prostate-specific membrane antigen)-targeted PET scanning in prostate cancer; therapeutic approach to M0 disease in patients who experience disease progression on androgen deprivation therapy (48:49) Benefits of early initiation of secondary hormonal therapy (57:06) Counseling patients about therapeutic options for mHSPC; considerations for clinical care in the COVID-19 era (1:01:08) Choice of secondary hormonal therapy for patients with metastatic prostate cancer (1:09:21) Selection and sequencing of therapy for patients with mCRPC (1:12:03) Management of disease that progresses on androgen receptor (AR)-targeted therapy; CARD trial of cabazitaxel versus AR-targeted agents for patients with previously treated mCRPC (1:16:34) Role of chemotherapy and PARP inhibitors for patients with prostate cancer and DNA damage repair gene alterations (1:20:02) CME information and select publications

Remdamasi Europos vaistų agentūros išvadomis, Lietuva atnaujina skiepijimą "AstraZenecos" vakcina nuo COVID-19. Vakar agentūra nurodė, kad skiepas nesukelia didesnės kraujo krešumo rizikos, dėl to jis yra saugus ir efektyvus. Sveikatos apsaugos ministras Arūnas Dulkys teigia, kad atnaujinant vakcinavimą "AstraZenecos" sukurtu preparatu, gyventojų ir skiepijimo centrų laukia naujovės.Prieš dešimt metų, 2011-ųjų kovą Sirijoje prasidėjo taikūs protestai, peraugę į vieną žiauriausių ir ilgiausių šių dienų kariiinių konfliktų. Ieva Balsiūnaitė.Lygių galimybių padėtis Lietuvoje. Pokalbis su Lygių galimybių tarnybos kontroliere Agneta Skardžiuviene ir kandidate į šį postą Birute Sabatauskaite.Kaip atsiveria ir funkcionuos muziejai?M0 muziejaus direktorė Milda Ivanauskienė, Lietuvos nacionalinio muziejaus viešųjų ryšių specialistas, Šiaulių „Aušros“ muziejaus direktorius, muziejų asociacijos vadovas Raimundas Balza.Ved. Rūta Kupetytė

I’m sponsored by Adafruit to work on CircuitPython. Support them, and by extension me, by purchasing hardware from https://adafruit.com Chat with me and lot of others on the Adafruit Discord at https://adafru.it/discord. Deep Dive happens every week. Normally Fridays at 2pm Pacific but occasionally shifted to Thursday at 2pm. Typically goes for two hours or more. Questions are welcome. Next week is on Friday. If you are outside the US, double check the time because the US is changing this weekend. Time change in USA 0:00 Getting things going 03:09 hello 06:56 housekeeping 11:25 How do you keep the cats away from the workstation and hot irons? 12:40 how far is circuitpython's implementation of asynchronous I/O scheduler (uasyncio)? 14:44 Is there a time you'd pick the STM32F405 Feather over the SAMD51 feather? They seem similarly capable, but Adafruit seems all-in on the SAMD51 16:10 there was no feather airlift so ordered 1 on digikey which has not even shipped yet Ordered another airlift yesterday from adafruit when it came back in stock so which one will show up first? 18:05 Feather RP2040 flash speed fix 18:34 OSHPark USBmicromod/v1 19:29 Are you using debug-edge in anything? Know anyone else who is using it? 24:58 SMT assembly at OSH Park ( no ) 25:11 how does OSH's flex pcb compare to the flex PCB on the neopixel/dotstar strips 26:41 Overhead / RP2040 feathers… flash socket 34:30 How big flash chip we can use with Metro/Feather M4 express? I tried mounting 64Mb but circuitpython didn't support it!!! 35:37 nvm.TOML improvements 38:43 Salea Logic Pro 16 work 40:52 Is there a good small library for ingesting uart stuff, and parsing into variables, in CP ? (for multi headed use cases) 41:19 back to the logic analyzer…. Examining the clock speed up during the boot process 51:10 Luke mentions RXDLY see boot2_w25q80.S for reference 55:46 Well it delays your sampling to the point in time where you launch the next clock transition which should still give you plenty of hold time because your data hold will be equal to round trip delay ​so RX_SAMPLE_DLY = 1 should be fine for BAUDR = 2 ha, I bet the second read is the hardfault vector fetch 58:35 - works one time when new software is installed, but not on power up 1:00:30 is there a good source to understand how PIO was implemented? Its not part of the M0 "platform", right? So I'm assuming it’s something uniquely developed for the RP2040 1:01:30 updating firmware again…. 1:06:09 Lady Ada drops in1 1:07:14 ItsyBitsy RP2040 prototype ( launching with 4MB flash? ) Discussion of Flash speed 1:17:30 - Luke added “there is more timing to play with -- for boot2_w25q80 we also disable input schmitt to get good setup timing. Have run the winbond devices at their max 133 MHz SCK reliably” ​(with RP2040 running a bit off-label :-) ) 1:21:11 ‘quad enable bit non-volatile’ frustration / warning…. 1:38:40 - catch desk of ladyada on Sunday! 1:39:15 bye LadyAda 1:39:30 Does this relate to the QT-Py flash? 1:40:02 so is there a volatile QSPI enable also? 1:41:25 Can Micro Python libraries work on Circuit Python? 1:42:06 Schmidt Trigger idea from Luke … 1:44:02 how do you get those cool colors and such in your terminal prompt?? 1:44:20 Scott’s quick build machine -j32 1:48:45 commit code before moving back to C… 1:52:40 Did you get the Pomona clip working from last week? 1:53:30 What are you not allowed to tell us ? 1:55:15 ​is that 2 x 5 SWD header difficult to solder on? 1:56:55 how many times is a decent test for reliability in this sort of case? 1:59:25 rebase code 2:00:30 responding to spam calls .. 2:01:00 pull request 2:02:30 why are you using Mac? and why not Linux? 2:03:29 so what do you use to capture the camera feeds? 2:05:14 wrap up 2:06:28 sign off 4:07pm... ----------------------------------------- LIVE CHAT IS HERE! http://adafru.it/discord Adafruit on Instagram: https://www.instagram.com/adafruit Subscribe to Adafruit on YouTube: http://adafru.it/subscribe New tutorials on the Adafruit Learning System: http://learn.adafruit.com/ -----------------------------------------

távfűtési anomáliákGergőéknek 1 éves lesz az új fűtésükNetatmoAntenna albérlet keresésekbenkaucióBence pörgeti tovább a kamion kormányáthorrorkaravánok büntetésehihetetlen helyzet az M0-ásonrádiók az Apple musicbanközeleg a határidő avagy Gergő tartalmat fogyasztDumaTVAntenna racionalizálja eszközeit és kiadásaitGergő újra Fuji fényképezőt venne3D nyomtatott kamera Twitterünk - Kotyogós podcast officialAntenna twitterenGergő twitterenBence twitterenÍrhatsz nekünk e-mailt: kotyogospodcast@gmail.comHa meghívnál minket egy kávéra és ezzel hozzá szeretnél férni a specialty tartalmunkhoz megjelenés pillanatában:Patreon támogatásHa beszélgetni akartok velünk és hallgatótársaitokkal akkor Telegramon is megtehetitek ha a "t pont me per kotyogos"-ra mentek.

Featuring perspectives from Drs Emmanuel S Antonarakis and Andrew J Armstrong on the following topics: Introduction (0:00) When should postprostatectomy radiation therapy generally be recommended? (2:45) When should the oral GnRH receptor antagonist relugolix be recommended if it were available? (4:17) When should ADT for PSA-only relapse (M0) after local therapy be recommended? (9:26) When should an antiandrogen agent be added to ADT for castration-resistant M0 prostate cancer? (14:04) When do you use prostate-directed local therapy for mHSPC? (22:19) When do you add an antiandrogen agent, abiraterone or docetaxel, to ADT for mHSPC? (Selection of agent) (24:13) How do you generally approach the selection of endocrine treatment versus chemotherapy after first-line endocrine therapy for mCRPC? (31:58) How do you generally approach the use of radium-223 for mCRPC? (34:25) How do you generally approach the use of PARP inhibitors for mCRPC? (37:07) What is known about PSMA-targeted treatment and imaging in prostate cancer? (54:05) What is known about TMPRSS2 and COVID-19? (58:19) CME information and select publications

Prostate Cancer Update, Issue 1, 2021 — Part 1: Our interview with Dr Saad highlights the following topics as well as cases from his practice: Optimal integration of secondary hormonal therapy into the management of nonmetastatic castration-resistant and metastatic hormone-sensitive prostate cancer — Presentation (0:00) Results of the Phase III HERO trial evaluating relugolix, an oral GnRH receptor antagonist, versus leuprolide for advanced prostate cancer (21:42) Perspective on the benefits of early initiation of secondary hormonal therapy for patients with prostate cancer (29:20) Role of immunotherapy for prostate cancer; optimal timing for the initiation of androgen deprivation therapy (ADT) for patients with M0 disease (33:34) Phase III HERO study comparing relugolix to leuprolide for advanced prostate cancer (39:37) Prevention and management of side effects associated with ADT (45:39) Impact of PSA doubling time on eligibility and outcomes of patients with nonmetastatic castration-resistant prostate cancer (CRPC) who received enzalutamide, apalutamide and darolutamide in the Phase III PROSPER, SPARTAN and ARAMIS trials, respectively (49:50) Efficacy and tolerability of enzalutamide, apalutamide and darolutamide in the PROSPER, SPARTAN and ARAMIS trials for patients with nonmetastatic CRPC (53:56) Benefits and risks with enzalutamide, apalutamide and darolutamide (58:52) Outcomes with the addition of docetaxel versus abiraterone to ADT for metastatic hormone sensitive prostate cancer; impact of disease burden on therapeutic decision-making (1:05:02) Novel agents and approaches under investigation for patients with prostate cancer (1:12:49) CME information and select publications

🎈 Breaking‌ ‌News‌ ‌-‌ ‌BofA señala a Bitcoin como una gran burbuja, altcoins en alza esta semana - El Bank of America (BofA) dice que la reciente alza de Bitcoin es la burbuja más grande en su historia, mientras que varias altcoins superan a BTC con rendimientos semanales de hasta el 130%. Estas‌ ‌y‌ ‌más‌ ‌‌noticias‌ en‌ ‌este‌ ‌práctico‌ ‌resumen‌ ‌diario para‌ ‌que‌ ‌siempre‌ ‌estés‌ informado ‌con‌ ‌los‌ ‌acontecimientos‌ ‌más‌ ‌recientes‌ ‌que‌ ‌ocurren‌ ‌dentro‌ ‌del‌ ‌mundo‌ ‌crypto.‌ ‌ https://news.bit2me.com/bofa-senala-a... 🇨🇳 China sigue dando pasos hacia el Yuan digital. - e-CNY, aunque utiliza blockchain, es una sustitución centralizada del dinero M0 de China (billetes, monedas). El pago fuera de línea y anónimo garantiza que solo el PBOC pueda rastrear el flujo de dinero. - En el futuro, los comerciantes pueden rechazar AliPay / WeChat Pay, pero tienen prohibido rechazar pagos en e-CNY. - Este anuncio se ha realizado desde la cuenta oficial de Ledger, 🇫🇮 Finlandia venderá casi 2.000 BTC confiscados en procedimientos de incautación - La Autoridad de Aduanas dijo que después de evaluar sus opciones, de entregar los BTC a otra organización o destruirlos, la mejor opción era vender, después de que los BTC confiscados se revalorizarán en más de 4.500%. - La Autoridad de Aduanas de Finlandia, Tulli, venderá cerca de 2.000 BTC incautados en diferentes procedimientos para beneficiarse de su revalorización y del reciente rally alcista que llevó a la criptomoneda a tocar los 42.000 $ USD por unidad. https://news.bit2me.com/finlandia-ven... 🪃 Precio de Bitcoin a 36.500 dólares rebote del 15% - Las Altcoin también han rebotado con fuerza - El mercado parece estar buscando una consolidación sobre los 36.000 aunque sugieren precaución porque la corrección podría continuar. - En el 2017 cuando vimos la primera corrección testeamos los máximos de Bitcoin que por entonces eran de 1000 dólares viniendo desde 1300 - El siguiente impulso alcista llevo a Bitcoin a unos 4000 dólares, muchos creen que la historia se está repitiendo pero que este tipo de correcciones son importantes para establecer una base y seguir subiendo 💵 Nuevo paquete de estímulos de Estados Unidos puede impulsar el precio de Bitcoin - Ante la devaluación del valor del dólar por la masiva impresión de dinero fiat, Bitcoin se presenta como la mejor alternativa de refugio de valor, capaz incluso, de generar riqueza generacional - Para sobrellevar las consecuencias económicas de la pandemia mundial del COVID-19, Estados Unidos comenzó a implementar, desde marzo de 2020, paquetes de estímulos para contener el impacto económico de la pandemia, e impulsar la “rápida recuperación económica” del país, según la Cámara de Representantes de Estados Unidos. En marzo, el primero de estos paquetes fue aprobado por valor de 2,2 billones de dólares; cerca del 10% del producto interno bruto (PIB) del país. - Europa también impone nuevas medidas económicas https://news.bit2me.com/paquete-de-es... 🚀 Suscríbete a nuestro Canal: https://www.youtube.com/channel/UCBiA... 00:00 Sumario 0:25 Primera Noticia 1:28 Segunda Noticia 2:23 Tercera Noticia 3:27 Cuarta Noticia 4:33 Quinta Noticia 5:56 Pregunta del día 6:11 Cierre #Bitcoin #Burbuja #YuanDigital #Blockchain #Criptomonedas 🎁 *¡Has descubierto un regalo!* Si estás aquí, aprendiendo, te mereces nuestro regalo especial: Regístrate en Bit2Me con este enlace y en tu primera compra de 100€ o más te regalaremos 5€: https://bit2me.com/?r=75N-GP4-G0S *¡La revolución la creamos entre todos!* 📲¡Descárgate la APP! https://bit2me.com/download Compra y vende Bitcoin , Ethereum , Litecoin , Dash, Bitcoin Cash , Ripple y otras criptomonedas . Soporte telefónico en Español . Con tarjeta VISA / Mastercard , transferencia y dinero en efectivo . El mejor monedero ( wallet ) crypto. Nuestra web: https://bit2me.com 👉 Síguenos en las redes sociales: ➡ Facebook: https://www.facebook.com/bit2me ➡ Instagram: https://www.instagram.com/bit2me ➡ Linkedin: https://www.linkedin.com/company/9243641 ➡ Twitter: https://twitter.com/bit2me ➡ Telegram: https://t.me/Bit2Me_ES ➡ Spotify: https://open.spotify.com/show/1Tj4kyX... ➡ iVoox: https://www.ivoox.com/podcast-bit2me-... y por supuesto, dale a la campanita para activar las notificaciones 👈 ✍🏻 ¡Apunta! Conoce todos nuestros servicios: ➡ Wallet: https://bit2me.com/wallet ➡ Tikebit (compra criptomonedas en tiendas físicas): https://www.tikebit.com/inicio&lang=es ➡ Academy: https://academy.bit2me.com ➡ Crypto TV: https://tv.bit2me.com ➡ Crypto Converter: https://converter.bit2me.com ➡ Agenda de crypto eventos: https://agenda.bit2me.com ...y muchos más en nuestra web! 📲¡Descárgate la APP! https://bit2me.com/download

We know that many of our listeners are in the depths of a tough COVID Winter in the Northern Hemisphere, so we thought we might bring you some summer cheer from Australia where the sun is shining and COVID is less of an issue! We have joined with our friends at PROSPECT, a prostate cancer educational initiative which has been running in Australia for eight years. to bring you a 3-part podcast summer series focussing on our favourite hot topics in prostate cancer. Today we focus on two areas with a big crossover - so-called "non-metastatic (M0)" castration-resistant prostate cancer (CRPC), and PSMA PET/CT. The past year has been a bog one for PSMA PET/CT and we are delighted to welcome two of the world's leading experts in PSMA PET/CT, Professor Michael Hofman from Peter MacCallum Cancer Centre in Melbourne, and Dr Jeremie Calais from the University of California, Los Angeles, to discuss the recent FDA approval and the data that has informed this. Plus we are joined by Associate Professor Arun Azad, Medical Oncologist at Peter MacCallum Cancer Centre and Chair of the PROSPECT Steering Committee, to discuss the overall survival data for androgen receptor pathway inhibitors in M0 CRPC, and to consider what wider availability of PSMA PET/CT means for this disease area. Your usual hosts are Professor Declan Murphy and Dr Renu Eapen from Peter Mac. PROSPECT and our GU Cast Summer Series are supported by an educational grant from Janssen Oncology in Australia. 

各位链团财经的读者朋友们，大家早上好。欢迎收听链团财经早资讯。今天是2020年12月16日星期三，农历庚子年十一月初二，首先让我们聚焦国内新闻：统计局:下阶段中国经济有望成为世界主要经济体中唯一正增长的国家力争在法定数字货币等领域深度参与国际标准规则制定美国FTC要求亚马逊、Facebook等科技公司解释如何使用用户信息 苹果和谷歌研发的新冠联系人追踪程序“CANotify"加州正式上线下面我们走进区块链领域：美国CFTC技术团队：DeFi平台非法运作难追责 次要责任或威胁DeFi协议参与者美国怀俄明州新任参议员：应有明确途径允许比特币与法币一起发展浙江省市场监管局：启动区块链电子取证平台移动端上线 北京市政府副秘书长：将利用冬奥会等场景深化数字货币创新超半数受访者预计到2030年BTC将达到或低于2万美元研究显示：11月以来比特币新矿机价格飙升35% 澎湃新闻关联公司入股鲨丁区块链 住建部等六部门：广泛运用大数据、区块链等人工智能等技术，建设智慧物业管理服务平台Ripple首席技术官：比特币可抵御系统中黑客或漏洞的长期威胁周小川：数字人民币不会取代美元，也不会威胁全球货币体系（更多详细内容请关注公众号 “链团早资讯”） 据中国网财经消息，12月15日，由中国互联网金融协会等主办的2020第四届中国互联网金融论坛在京召开。财政部原副部长朱光耀在演讲中表示，数字货币的问题有特殊规律，同互联网的发展、区块链的发展密切结合在一起。去年，脸书把对数字货币的争论在世界范围内提到一个新的战略高度。这个问题我们确实要警惕，而且要从战略角度进行研究。研究这个问题，一定要坚持多边主义原则，而不是像目前以美国为首的西方国家孤立、垄断地在西方七国内研究，这是错误的方向，而且不会得到结果。另一方面，其他国家应该充分认识这个问题的战略性，推动在这个问题研究上的多边合作。与此同时，推动由中央银行发行的数字货币，中国的中央银行走在前列。同时我们要清醒，我们现在研究的数字货币是M0的一种补充形式，还是在零售环节，而不是货币的所有功能。所以，这个问题同样要从战略高度进行更深一步的研究。 以上就是今天链团财经早间资讯的全部内容，欢迎转发分享，如果您有更好的建议，请扫描文末二维码与主播分享。感谢您的关注与支持，祝您生活愉快，我们明天再见。

Születésnaposok, névnaposok, évfordulók említése után Budapest, te csodás rovatunkban az M0-as botrányhídjáról, 3-as metró felújításról és az eltűnő a Fontana épületről esett szó. Célegyenesben a szuperbank! Péntek esti a bejelentés, megvannak a pontos tulajdoni arányok, vezetők. De hogy fognak tudni ők együtt dolgozni? Csabai Károly, az Mfor.hu-Privátbankár.hu lapcsoport felelős szerkesztője számolt be a fejleményekről. Elnökválasztás és kamatdöntés Amerikában, BMI és ipari termelés itthon. Tardos Gergely, az OTP Elemzési Központ vezetője foglalja össze az aktuális helyzetet. Új rovatunk indul Karikacsapás néven, amiből az is kiderül, Mi az FM, avagy létesítmény üzemeltetés? Mi tartozik bele és mi nem? Erről Szij Csabát, a B+N Referencia Zrt. vezérigazgató-helyettesét kérdeztük.

Proceedings from the eleventh in a series of 11 integrated webinars held in association with the 2020 ONS Annual Congress. Featuring perspectives from Dr Robert Dreicer, Ms Kara M Olivier, Ms Victoria Sinibaldi and Dr Matthew R Smith. Introduction (00:00) Overview of prostate cancer treatment (3:25) Management of M0 prostate cancer (27:17) Management of metastatic hormone-sensitive prostate cancer (45:01) Management of metastatic castration-resistant prostate cancer (mCRPC); emerging agents and strategies (1:04:48) CNE information and select publications

宏观经济【央行副行长：数字人民币不计付利息】央行副行长范一飞近日在金融时报发布文章称，数字人民币主要定位于M0，是法定货币的数字化形态，发行和流通要按照现金进行规范管理。数字人民币不计付利息，具有非盈利性，追求的是社会效益和社会福利最大化。因此，人民银行对数字人民币执行与现金一致的免费策略。央行不向发行层收取兑换流通服务费用，商业银行也不向个人客户收取数字人民币的兑出、兑回服务费。A股总市值增长3.2万倍。【A股上市公司本周将突破4000家】中国股市自1990年开市以来，已走过30载，本周，A股上市公司数量将突破4000家。截至9月11日，A股总市值达76.64万亿元，相比1990年底“老八股”增长了约3.2万倍。从募资规模看，农业银行、中国石油、中国神华IPO募资额均突破600亿元，位列前三；从总市值看，茅台总市值超过两万亿元一马当先，工行、中国平安、建行、农行、中国人寿紧随其后，均超过万亿。20年间，A股共产生了77家真正意义上的退市公司。产业纵深【中华老字号现状：近一半持续亏损，近九成老字号经营面临压力】2006年及2011年，商务部先后确定了两批中华老字号名录，企业总计1128家。这其中，一半以上为国有企业，平均年龄约142岁。据商务部统计，在现存的1128家中华老字号中，仅10%的企业蓬勃发展，40%的老字号勉强实现盈亏平衡，而近一半都是持续亏损状态。（新京报）【报告：清华大学毕业生月薪达1.7万】智联招聘14日发布的一份报告显示，2020届毕业生第一份工作平均起薪为5290元/月，机械工程专业以6851元月薪位居榜首。根据2019届毕业生平均月薪榜单，清华大学以17682元/月名列榜首，北京大学（15365元/月）、上海交通大学（11199元/月）、浙江大学（11137元/月）位列其后。企业动态阿里又有大动作？【阿里动物园又要增加新成员？阿里将宣布保密3年新业务】多家媒体收到“9月16日阿里巴巴动物园，有新动物出没”的神秘邀请函，邀请函上一只梅花型的动物脚印引起外界猜测。记者获悉，阿里巴巴确实将在周三宣布新业务，属于一项全新的赛道，而且已在阿里保密3年，内部少有人知道。【百度网盘疑推出国际版Dubox，提供1TB空间和不限速下载】9月14日，网友爆出百度网盘国际版Dubox推出公测，ios和安卓用户均可下载客户端，新用户可使用1TB的空间和不限速下载，该网盘服务不提供给中国大陆用户使用。其官网页面设计与百度网盘十分相似。资料显示，百度于2020年4月申请注册了Dubox商标，其国际分类为网站服务。据网友体验，上传速度能够达到10M/s，下载速度最高达2M/s。【步长制药又曝贿赂医生！开35962盒脑心通胶囊，回扣12万元】2016年以来，商水县人民医院主治医师王海生利用职务便利，非法收受步长制药销售业务员苏某药品回扣款人民币125000元，在2016-2019年间，一共开具步长脑心通胶囊35962盒。经核算，每开一盒步长脑心通胶囊，王海生就能拿到3.3元的回扣。最终因其犯罪情节轻微，被免予了刑事处罚。脑心通，正是步长制药的王牌，同时也是该公司争议最大的药品。涉诉资产处置完毕。【安邦保险集团将申请解散并清算】9月14日，安邦保险集团公告，安邦保险集团股份有限公司召开股东大会，会议决议解散公司，并成立清算组（筹）。下一步，公司将按照法律法规向中国银保监会申请解散，在取得相关行政许可后及时组织清算。【华为新增两件“仓颉语言”商标，为自主研发编程语言】近日，华为新申请两件“仓颉语言”商标。状态为“申请中”，国际分类为第9类及第42类，其中第9类中包含计算机及手机相关的软件程序商品，第42类则包含计算机编程服务等。据媒体报道，“仓颉”为华为自主研发的编程语言。（证券时报）国际视野【日本新首相定了】14日，日本自民党总裁选举结果公布。内阁官方长官菅义伟（71岁）以377票的显著优势获胜。目前日本自民党占有国会多数议席，菅义伟作为新任自民党总裁，将接任安倍晋三成为日本首相。根据法律程序，日本政府16号将召开临时国会，正式任命新首相。（央视新闻）在美能否过关？【TikTok出售改为和甲骨文合作,不涉及出售和技术转让】据CNBC报道，甲骨文确认了美国财长姆努钦的声明，即财政部在周末接到提案，甲骨文将作为TikTok可信赖的数据安全合规合作伙伴，代表解决美国国家安全问题。该方案是甲骨文作为数据合规伙伴，类似苹果在中国由云上贵州进行数据合规的方案，并不涉及之前特朗普提到的要求TikTok出售，也不涉及TikTok的核心技术转让。（证券时报网）全球芯片业巨震！孙正义将ARM卖给美国公司：【英伟达400亿美元从软银手中收购ARM，尚需中国等批准】9月13日，英伟达宣布与软银达成最终协议，将以400亿美元的价格从软银手中收购Arm。英伟达将向软银支付总计215亿美元的股票和120亿美元的现金。交易完成后，软银预计将保留Arm不到10%的股份。此项交易尚须获得中国、美国、欧盟和英国的批准，预计监管审批可能需要长达一年半的时间。英伟达方面在官网上宣布，他们将为收购交易进行融资。【英欧汽车产业警告：无协议脱欧或致1100亿欧元损失】英国和欧洲23个汽车产业协会在一份联合声明中称，若英欧无法达成贸易协议，意味着汽车行业将被征收关税。这将使得汽车价格上涨，并导致需求下降，可能在未来五年使汽车产量减少300万辆。这可能使欧盟工厂和英国工厂分别损失577亿欧元和528亿欧元。

Welcome to the 1 Bitcoin Show! Is 10k the normie number that has become a psychological bottom? Since stablecoins are censorable can one expect a major bank to take over one of today's major players? For secular people BTC is an asset you can take with you when you die. By the M0 monetary measurement, BTC is already a major player. SJW drama in Bitcoin development land over the term blacklist? Crypto battles as a pastime? Much more! Recorded in Asheville, NC! Watch the show here-https://www.youtube.com/watch?v=p8fimQyb4lc Follow Adam on Twitter- https://twitter.com/TechBalt All of the BitcoinMeister videos are here at- http://DisruptMeister.com Financially support the podcast here- https://anchor.fm/bitcoinmeister/support BOOKMARK SPORTSMEISTER.com DISRUPTMEISTER.com & TECHBALT.com --- This episode is sponsored by · Anchor: The easiest way to make a podcast. https://anchor.fm/app Support this podcast: https://anchor.fm/bitcoinmeister/support

Optimista pénteken sem maradhat el a név- születésnaposok köszöntése, illetve a történelmi események felidézése. Miként a lapszemle és a tőzsdei összefoglaló sem. Budapest rovatunkban hírcsokor van, de kiemelten az M0-as déli szakaszán található Duna-híd elhúzódó felújításáról szólunk. A fesztiválszezonnak idénre annyi, a kormány nem oldja fel a járványvédelmi korlátozást. Ez nagyon nagyon fáj a zeneiparnak. Miért? Horváth Péter (ProArt) feltárja a hátteret. Értékpercek treasury rovatunkban nyersanyagpiac. Történelmi csúcson az arany, szárnyal az ezüst. Merre tovább? Fábián Lóránt (OTP Global Markets) válaszol. Arra is, hogy a korábban szenvedő olajár, most épp merre tart?

5 - Nyilatkozat az M0-ás hídról by Balázsék

Kész lesz-e a valaha az M0-ás? Van-e értelme a Volánbusz-MÁV fúziónak? Miért esett szét az Űllői út forgalma? Andó Gergelly, a Közlekedésvilág lapcsoport lapigazgatójával beszélgettünk. Ép testben: Kékszalag 2020 - Holczhauser András, a Magyar Vitorlás Szövetség főtitkára.

Llega a su fin esta 1ª temporada de Finect Talks, y por ello mismo hemos querido estar todo el equipo del podcast presente para repasar qué programas han sido los más escuchados de la cerrar con una pregunta: ¿Cuál ha sido la peor inversión de tu vida? ¿Y cuál la mejor? ¡Os leemos en comentarios! Durante el podcast: - Antonio Villanueva trae qué podcast han sido los más escuchados de esta temporada - Comentamos nuestras mejores y peores inversiones - Carlos Alosete comenta los mejores fondos de inversión 2020 y los mejores a tres años. - Asun Infante habla de las mejores cuentas remuneradas con datos actualizados a julio. - Sara Rivas nos trae la guerra de comisiones que se está librando ahora mismo en el mundo de los gestores automatizados en España y del ebook que hemos hecho en Finect con toda la información al respecto (ver abajo enlaces) - Por último, analizamos una canción del Fary muy curiosa dedicada al dinero y nos echamos unas risas con ello. ¡Muchas gracias a todos/as por acompañarnos en estos 42 programas! Volvemos en septiembre con más Finect Talks :) ENLACES PODCAST 1x42 - Buscador gratuito de asesores financieros en Finect: https://bit.ly/3051GNM - Compara y contrata todos los roboadvisors en Finect con las mejores promociones: MyInvestor, Indexa Capital, Popcoin, Inbestme... https://bit.ly/2ZtqHTW - Descárgate aquí gratis el ebook de roboadvisors: https://bit.ly/38VWYG4 - Mejores cuentas remuneradas en España (actualizado): https://www.finect.com/usuario/AsunInfante/articulos/mejores-cuentas-remuneradas - Fondos inversión más rentables 2020: https://www.finect.com/fondos-inversion/listado?country=esp&order=-M0

Llega a su fin esta 1ª temporada de Finect Talks, y por ello mismo hemos querido estar todo el equipo del podcast presente para repasar qué programas han sido los más escuchados de la cerrar con una pregunta: ¿Cuál ha sido la peor inversión de tu vida? ¿Y cuál la mejor? ¡Os leemos en comentarios! Durante el podcast: - Antonio Villanueva trae qué podcast han sido los más escuchados de esta temporada - Comentamos nuestras mejores y peores inversiones - Carlos Alosete comenta los mejores fondos de inversión 2020 y los mejores a tres años. - Asun Infante habla de las mejores cuentas remuneradas con datos actualizados a julio. - Sara Rivas nos trae la guerra de comisiones que se está librando ahora mismo en el mundo de los gestores automatizados en España y del ebook que hemos hecho en Finect con toda la información al respecto (ver abajo enlaces) - Por último, analizamos una canción del Fary muy curiosa dedicada al dinero y nos echamos unas risas con ello. ¡Muchas gracias a todos/as por acompañarnos en estos 42 programas! Volvemos en septiembre con más Finect Talks :) ENLACES PODCAST 1x42 - Buscador gratuito de asesores financieros en Finect: https://bit.ly/3051GNM - Compara y contrata todos los roboadvisors en Finect con las mejores promociones: MyInvestor, Indexa Capital, Popcoin, Inbestme... https://bit.ly/2ZtqHTW - Descárgate aquí gratis el ebook de roboadvisors: https://bit.ly/38VWYG4 - Mejores cuentas remuneradas en España (actualizado): https://www.finect.com/usuario/AsunInfante/articulos/mejores-cuentas-remuneradas - Fondos inversión más rentables 2020: https://www.finect.com/fondos-inversion/listado?country=esp&order=-M0

Donate to DJ Carl© today! URGENT: Make a donation with Zelle® to carl@djcarl.com or PayPal® - http://bit.ly/2tAQAhs DJ Carl© Playlist: 01. Teyana Taylor f. Ms Lauryn Hill – We Got Love 02. 2 Chainz f. Lil Wayne – Gotta Lotta (P) 03. Drake – Toosie Slide 04. Bill Withers – Lovely Day (V) 05. Wyclef Jean f. John Forte & Pras – We Trying to Stay Alive 06. Major Lazer & DJ Snake f. M0 – Lean On 07. Mavado f. Akon & Rick Ross – Rise Up 08. Roddy Ricch f. Mustard – High Fashion 09. Tony Toni Tone f. DJ Quik – Let's Get Down 10. 2 Pac f. Eric Williams – Do for Love 11. Dej Loaf – No Fear 12. The Weeknd – In Your Eyes 13. H.E.R. f. YG & A Boogie Wit Da Hoodie – Slide 14. 112 f. The Notorious B.I.G. & Mase – Only You (P) 15. Eve – Tambourine (P) 16. Soul for Real – If You Want It (V) 17. Akon f. Styles – Locked Up (V)=Voiceover (S)=Shoutout (P)=Promo

TRANSCRIPT Welcome to the ASCO Daily News Podcast. I'm Geraldine Carroll. The Genitourinary Cancer Symposium hosted by ASCO in San Francisco revealed some significant clinical developments, and here to discuss key takeaways from the meeting is Dr. Karen Knudsen, program chair of the symposium. Dr. Knudsen is the enterprise director of the NCI-designated Sidney Kimmel Cancer Center at Jefferson at Thomas Jefferson University and Executive Vice President of oncology services at Jefferson Health. Dr. Knudsen, welcome to the Daily News Podcast. Dr. Knudsen: Thank you so much for having me. It's really a pleasure to get a chance to discuss all of the things that were revealed at the 2020 ASCO GU. ASCO Daily News: Dr. Knudsen, do you have any conflicts of interest that you'd like to disclose, which are relevant to our conversation? Dr. Knudsen: If I do have conflicts of interest, I don't think they're relevant for the conversation. But I like to disclose them anyway. As the cancer center director, it's something all of us are trying to pay more attention to. So I do have advisory and consultant positions with CellCentric and Genentech. I've had ad hoc advisory board positions in the last two years with Sanofi, Janssen, Novartis, and Celgene, and research support from CellCentric and Celgene. ASCO Daily News: All right, thanks Dr. Knudsen. Well, the Genitourinary Cancer Symposium showcased a lot of interesting presentations and insights on topics across GU malignancies. So what are your key takeaways from the meeting? Dr. Knudsen: So this was really an exciting meeting for us, and the way that we put together the program was aligned to our theme, which is, in pursuit of patient-centered care. And the program committee and steering committee really worked together to try to decide how the 2020 program should come about. And it was to take all of the things that were and are fantastic about ASCO to you and take it even further in a couple of different directions. Dr. Knudsen: One is to incorporate really the latest science, the latest evidence for some of the new agents and new interventions that we're seeing develop for GU malignancies, and also look to the future of things that are coming. The second was an emphasis on multidisciplinary teams, so effective integration of urology, medical oncology, and radiation oncology as related to GU cancers, but also the translational science behind the new findings and seeing those come together. Dr. Knudsen:  And then the last was a focus on quality of life. As we've had all these new interagents and new interventions introduced over the last few years in the GU malignancy field, we felt it was really important for us to ensure that we're addressing impact on quality of life, including but not limited to financial toxicity throughout the meeting. And I think those elements were really achieved by dissection of the program, but also, we've heard just tremendously positive feedback from attendees about that additional incorporation and thoughtfulness within the meeting. Dr. Knudsen: So you know, kind of keeping that in mind, I think that some of the key takeaways are that the pace of our field is really moving quickly with regard to innovative imaging, combinations, especially novel combinations using immunotherapy as a backbone. We heard about new endpoints, PSS2, new biomarkers, and incorporation of targeted agents. So across all of the GU malignancies, there was this feeling that the pace has really accelerated for new opportunities for detection and intervention. Dr. Knudsen:  In order to also really address what some of those new possibilities are, we had something quite different this year. We had the FDA with us in a, quote unquote, meet the regulators session to talk about some of these new technologies, new endpoints. And they actually walked us through a previous example of something that had come to light in the last few years in the GU field, which is incorporating the MSF or metastasis-free survival endpoint into GU malignancy trials. And that was a really important one. Dr. Knudsen: We also had some great reminders about how to ensure that our science and our clinical trials are tending to both statistical and clinical relevance. Fantastic statistical talk from Dr. Sides, who walked us through some of the ways that we can sharpen our focus on ensuring that we're drawing the right conclusions from the trials and the preclinical studies that we cover. Dr. Knudsen: And attendant to the theme of the meeting, we had a really fantastic keynote lecture from Dr. Dave Penson at Vanderbilt on financial toxicity and the impact on quality of life, as well as other endpoints, including patient-related outcomes and the overall outcomes from new interventions. He educated us about coping behaviors that patients engage in that may shift their compliance for cancer care and certainly, as may be related to other adverse events, and really shared with us some striking data about the number of patients that may be depleting their total net worth after a cancer diagnosis. So that part was really a call to arms to have all of us help attend to educating the patient as much as possible about financial ramifications, as well as other ramifications of therapies as they're introduced. So really, fantastic science, moving very quickly, and now we're ready to address some of the other ramifications of the newer interventions that we're introducing. ASCO Daily News: Speaking of new interventions, were there advances reported that would likely support new standards of care moving forward? Dr. Knudsen: There were. I think there-- you know, there were a number of advances that we're going to want to really track carefully over this next year. So advances in imaging were prominently discussed at the meeting-- when to use next generation imaging and taking into account disease state and clinical scenarios. Advances in standard of care are likely to also include-- we heard a lot about this at the meeting-- an increased incorporation of genetics, including both somatic and germline alteration. Dr. Knudsen: Dr. Castro gave us a really fantastic talk about the importance of profiling both somatic and germline alterations in patients, especially patients with advanced disease or who are at risk for aggressive disease, and showed us some compelling data about the limitations and ramifications of only looking at one, either somatic or germline. And that's probably not serving the patient as well as we could-- and gave us some very strong examples, especially with regard to DNA repair mutations, about how to incorporate this and to tailor therapy. Dr. Knudsen: I think that we'll see some changes coming in the future with regard to gene signatures and biomarkers. For example, even just in the prostate space, we heard about a 22 gene signature from Dr. Feng, which may predict who is going to need more aggressive care, as well as from Dr. Klotz with regard to non-coding RNAs and their ability to predict prostate cancer behavior. Dr. Knudsen: So this is actually a really interesting session, because we got into the dynamics of how we actually bring this to a change to [INAUDIBLE] where one of these signatures become standard of care, given the long-term follow-up that's really required to understand how these signatures inform prostate cancer behavior. So there was actually quite some healthy debate on that within the ASCO GU meeting. Dr. Knudsen: More forward thinking to later on was with some discussions with Dr. Beltran on epigenetics and how that may additionally influence our ability to predict behavior. But I think what I would say is probably the third and really interesting advance that we heard about at this meeting was our ability to use liquid biopsy and to have cell-free DNA or circulating tumor DNA inform the mechanisms of resistance that may be emerging in a particular tumor, and how we may treat that patient by anticipating and forwarding resistance. So a lot of really fantastic talks incorporated ctDNA into their discussions. Dr. Wyatt really stands out there in one of his discussions about the limitations of using circulating tumor DNA, but how promising this is with regard to giving concordance with what tumor lesions actually look like. So these are some technologies that are not quite ready yet to be incorporated as standard of care, but it's coming quickly. Dr. Knudsen: The future is really near, and so those are, I'd say, were some of the forward-thinking things that we really discussed, which, of course, complemented the exciting trial data that we saw, things that have been reported out and are likely to give new approvals and new interventions for GU malignancies in the near term. ASCO Daily News: You spoke about the prostate space a few moments ago. So I'm wondering, did any GU fields stand out more than others at this meeting? Dr. Knudsen: You know, I think each of the fields have had significant progress, as evidenced by some of the clinical trials that we heard about. So for example, in the clear cell renal carcinoma space, there was a lot of excitement over Dr. Choueiri's talk looking at a new target. So there was a Phase 1/2 trial for a first in class agent that's targeting a protein called HIF-2 alpha. And utilization of this oral HIF-2 alpha inhibitor and advanced clear cell renal carcinoma. Dr. Knudsen: So in this particular study, this new agent and the idea of targeting HIF-2 alpha actually emanated from what was the basis of the Nobel Prize in this last year with regard to understanding the factors that drive hypoxia and that are so important in this disease. And what was really remarkable about that Phase 1/2 trial is that there were objective responses seen in all of the different risk categories. So of course, the favorable category, but also the intermediate and poor risk category patients benefited from this agent. Dr. Knudsen: And so this is really, I think, one to watch. There's a large Phase 3 trial, as we understand it, on the way for this agent. So you know, clear cell-- that was just one of the things that we talked about. In the bladder cancer space, there was the NEOBLADE study, which is a neoadjuvant chemotherapy study, which was really interesting and was the basis of a lot of discussion as well, because the primary endpoint may not have actually achieved the benefit, which is a path CR. But there was improved PSS and overall survival as well in those patients. So that's also something really for us to watch and gives us new thoughts about what neoadjuvant chemotherapy might look like in bladder cancer. Dr. Knudsen: Another trial I think that was really interesting was the STOMP trial from Dr. Ost. So the primary endpoint for this study was something we don't always think about, which is androgen deprivation therapy free survival. That was really what was being tracked. And this is an interesting trial design. It wasn't designed to actually change practice, but to lay the foundation for a large Phase 3. And really, the question there for which the evidence looks quite interesting is, does metastasis direct to therapy improve this endpoint? Does ADT free survival? So I think that's one that was very forward-thinking type of strategy. Dr. Knudsen: And then not to underserve radiation oncology, because it was also featured very prominently at the meeting, and there were a lot of exciting results in a number of different formats. But the chip trial reported this long-term follow-up of a Phase 3 study looking at conventional versus hyperfractionated high dose radiation therapy in prostate cancer. And this was really a really good news outcome in that type of fractionation strategy appears to continue to be effective in these patients that require long-term follow-up. And certainly, prostate cancer at this stage is that category. So large number of trials that are on the cusp of being practice changing, and I just got a chance to mention a few. But in my view, all of the GU malignancies had these kinds of breakthroughs throughout the meeting that were reported. ASCO Daily News: That sounds very promising. And just finally, are there any other new agents in development or treatment approaches that really caught your attention and looked promising for the future? Dr. Knudsen: Yeah, I think there are. So in the prostate cancer space, there was significant discussion-- And this, I'm sure, will continue into GU ASCO 2021-- about the treatment of oligometastases and that oligometastases are really not the same as low volume disease. And that is going to be increasingly important for us as a field to understand the biology of oligomets. This may cause us to really redefine, as we can now image oligometastases much better with PSMA, attached agents just to redefine the M0 state and reexamine our thoughts about the trials that have happened in the past, or, perhaps, these patients actually were not at the MDR stage. Dr. Knudsen:  So that's one part of the oligometastases story. The other is, what is the impact of treating oligometastases? This is really where I think the field is moving. It's grappling with understanding that, and getting those trials to start to report out, I think, is going to be a really important thing for us to watch. In the muscle invasive bladder space, we talked and heard about the BLASST-1 trial from Dr. Gupta, which I think was also pretty exciting, exciting results with neoadjuvant, nivolumab, which [INAUDIBLE], and there was a report of the PCR in almost half of those patients. Think it was just under half of those patients-- really exciting. Dr. Knudsen: SGFR3 got a lot of discussion as a new target for bladder cancer, and there's a preview of what a Phase 3 trial might look like. But then there are also some studies that were really back to basics. They were incredibly important. So Dr. Plimack from Fox Chase Cancer Center here in Philadelphia gave a spectacular talk on side effect management. And this was for frontline treatment of renal cell carcinoma. Dr. Knudsen: And what she reminded us of is something incredibly important-- that strong side effects management, effective side effects management keeps patients on therapy and keeps them responding longer, and that we should not really undervalue this. It's something that's an important aspect of managing patients with advanced GU malignancies. And so as much as breakthroughs of new targets, new combinations, new ways to treat, new ways to image, but also, back to the patient centricity. Managing-- in this case, managing their side effects is a great way to get a better outcome. So important things to remember. ASCO Daily News: Absolutely. Well, I want to thank you, Dr. Knudsen, for sharing these interesting highlights from the GU Cancer Symposium. Dr. Knudsen: My pleasure. ASCO Daily News: And to our listeners, thank you for tuning in to the ASCO Daily News Podcast. If you're enjoying the content, please rate and review us on Apple Podcasts. The purpose of this podcast is to educate and to inform. This is not a substitute for professional medical care and is not intended for use in the diagnosis or treatment of individual conditions. Guests on this podcast express their own opinions, experience, and conclusions. The mention of any product, service, organization, activity, or therapy should not be construed as an ASCO endorsement. The following represent disclosure information provided by the guest(s) of this podcast: Dr. Karen Knudsen Consulting or Advisory Role:  CellCentric and Genentech. Ad hoc advisory board positions in the last two years with Sanofi, Janssen, Novartis, and Celgene, and research support from CellCentric and Celgene.  

Welcome to Finance and Fury, the Furious Friday Edition Welcome to FF FF – Hasn’t been a FF in a while – but last was running through Crypto markets in relation to the BIS and powers that be Today – Want to cover the potential of what central banks using crypto and by extension, all of us looks like This is a potential scenario for us – when – who knows? Maybe 2 years – 5 years – 15 or never happen – but Recent examples in the news - The Bank of England-authored Green New Deal (in 2008) and Synthetic Hegemonic Currency (takeover of Central Banking Crypto)  In this, they outline what the Bank of England’s Crypto might look like Another example - in BVI - Blockchain startup LifeLabs announced that it is developing a digital currency dubbed BVI~LIFE in partnership with the British Virgin Islands (BVI). The coin will be a stablecoin pegged 1:1 to the U.S. dollar — which the BVI have used since 1959 – pegging their fiat currency against the USD — and its use is expected to reduce transactional fees, increase transaction speed and be accessible to outsiders such as tourists What is a stablecoin?   Stablecoins are cryptocurrencies designed to minimise the volatility of the price compared to non-backed cryptos – like BTC How? - relative to some "stable" asset or basket of assets. A stablecoin can be pegged to a number of different things – can be cryptocurrency, fiat money, or to exchange-traded commodities (such as precious metals or industrial metals – like gold Similar to countries pegging their own currency to another – increase or decrease supply of your money base in response to maintain a peg – Compared to say BTC - perceived Advantages of asset-backed cryptocurrencies are that coins are stabilised by assets that fluctuate outside of the cryptocurrency space (unless pegged to another crypto) – reduces correlation risks – Bitcoin and altcoins are highly correlated - But even Backed stablecoins are subject to the same volatility and risk associated with the backing asset. A "stablecoin" which is neither stable or a coin - it is exactly a fiat derivative in the hands of Governments or Central Banks - a fiat derivative, it is not a move away from the dollar rather an extension of the dollar carried over crypto blockchains.   Why not BTC? – Stable coin will be required by the financial system – along with ability to regulate and control the backing of the currency (Gold or Fiat) – can't allow other currencies to continue if not backed by something that can be controlled – options to legislate to destroy confidence in any competing cryptocurrency – Will attack the Practicality of BTC first – Situation one – BTC is accepted by vendors using fiat currency – like currently – It can't have a base – to be accepted as a new type of financial system – just a derivative of the current through the pricing mechanics – we value it in AUD, USD or whatever you use day today Another currency could replace Businesses do currently accept BTC in exchange for AUD – But companies don’t want to get screwed through the floating exchange system – prices still in Fiat currency and the exchange is made for the equivalent value of BTC almost straight away Situation two – BTC is the valuation and companies have fixed exchange of goods to for BTC A basic car would cost 2 BTC – Would it be more profitable/secure to switch to accepting another currency? Also - BTC has a capped supply – So, alternative currencies would be adopted by people seeking the demand and profit from being early adopters - Currently thousands of coins – Viability – Unregulated and easily manipulated - Security in a cryptocurrency is everything – but the control by the monetary authorities is essential – excuse here will be that crypto like BTC is too risky for consumers due to the hacking/theft in the system – so will be banned as it is too risky to use Breaches have always been against currency exchanges and other ‘services’ that have grown up around Bitcoin – not the distributed ledger – so Gov’s/CB's can ensure the security of their own coins as the weak link of the wallets won’t exist   What do the options look like? – two viable options - between Fiat and Crypto Fiat-backed – issued and controlled by the state – the promise will be to secure and guarantee the distributed ledger Cryptocurrencies backed by fiat money are the most common and were the first type of stablecoins on the market. Their characteristics are: Their value is pegged to one or more currencies (most commonly the US dollar, also the Euro and the Swiss franc) in a fixed ratio, The tether is realised off-chain, through banks or other types of regulated financial institutions which serve as depositaries of the currency used to back the stablecoin, The amount of the currency used for backing of the stablecoin has to reflect the circulating supply of the stablecoin - Examples: TrueUSD (TUSD) USD Tether (USDT) Libra. Fiat-backed stablecoins can be traded on exchanges and are redeemable from the issuer. The cost of maintaining the stability of the stablecoin is equivalent to the cost of maintaining the backing reserve and the cost of legal compliance, maintaining licenses, auditors and the business infrastructure required by the regulator – not expensive to just push a button to issue more or less The value of stablecoins of this type is based on the value of the backing currency, which is held by a third-party regulated financial entity The trust in the custodian of the backing asset is crucial for the stability of price of the stablecoin – so the Fiat system will still need to be viable – Also other option – is SDR – basket of currencies backing the digital currency – like IMF are looking into Already being tested out in the financial system for proof of concept – but the real issue is the future of Fiat – amount printed and the lack of confidence in the USD spreading   I think there is another option which is in the works – Commodity-backed Stablecoins backed by commodities such as precious metals (gold, silver etc.) are much less likely to be inflated than fiat backed stablecoins. It is harder to mine gold or silver than it is to "create money out of thin air." The main characteristics of backed stablecoins are: Their value is fixed to one or more commodities and redeemable for such (more or less) on demand, There is a promise to pay, by unregulated individuals, agorist firms, or even regulated financial institutions, The amount of commodity used to back the stablecoin has to reflect the circulating supply of the stablecoin. Holders of commodity-backed stablecoins can redeem their stablecoins at the conversion rate to take possession of real assets. The cost of maintaining the stability of the stablecoin is the cost of storing and protecting the commodity backing. Examples: Digix Gold Tokens (DGX) and others. A lot of central banks around the world and trying to buy up on gold – hence why gold and miner demand has spiked   Real issues – example of what has occurred in the stablecoin market – The company/coin - Tether, the largest stablecoin by market capitalisation - faced accusations of being unable to provide audits for their reserves while continually printing millions of coins – who knows what the backing is? Reserves from Gov could be Fiat backing (M0) or Gold in their reserves So if these companies are likely able to easily do it - the gov is very likely to as well   What does this create for the future? – Remember – not saying it is a guarantee – but evolution of money does occur – helps to pay attention to potential future options But the monetary system has been used as a method of control A Fiat backed cryptocurrency system look like - These are merely central bankers’ wet dreams for depopulation and fascism “with a democratic face” which their 1933 conference failed to achieve These can only be imposed if people remain blind to their own recent history Sir Mosely – British Fascists Union – noble elite always want control over the population Talked about the attempted coup on the US government – But what commodities are other options – as Fiat is likely to not provide a good long term backing for crypto – gold as well – may not be the best backing due to the same issues of Brenton Woods – Gov may issue too much of the currency without adjusting the price of gold to give the currency a backing value Example – under fiat system – gold could be a backing if to go to gold standard – supply isn't the issue – price is the issue – Gov could increase gold price to $10k USD, or $14.5k AUD to match the required pricing But they historically have not responded well to this – due to self-interested policies -beggar thy neighbour situations - gain a competitive advantage in export prices – so gold can and had fallen apart as a monetary supply I’m not a fan of either option -   When it comes to depictions of events in the future - Art imitating life – or life imitating art Look at movie Intime – haven’t fully watched it – got bored 15m in – but concept is that time is used as a currency – This a form of cryptocurrency that your life is backing Seems crazy – carbon instead seems less crazy? Again – not saying that I think it will happen – but hear me out What is after gold? – the backing of this may break down again – like it did in the past many times as nations broke treaties or rulers debased the supply of currency versus gold/silver content – the next traded resource is carbon Might sound crazy – but the carbon trading scheme mechanism can create the bedrock of the laws needed to continue to create this system Rather than trading time – you trading your breathing Not saying that it is going to happen – but the legislation provides enough of a framework to implement – as it creates president on application to carbon emitters – which we are through breathing 3bn tons of CO2 a year – estimate for us breathing – a lot of CO2 if the goal by 2050 is to get to 0 CO2 emissions May take 100+ years to materialise – if it ever does – But ask someone over 100 years ago – that their money will not have gold backing it – that a Central bank controls their money and can increase the supply and control the cost of money through the interest rate – and be creating policies to control the inflation rate – or price increase of the economy – They would look at you like a loonie person Central bankers and nations are researching and working on crypto-backed currencies - need nations to adopt as currency – May ban Fiat ownership and replace with crypto first – Then have to move onto gold thanks for listening today. If you want to get in contact you can do so here: http://financeandfury.com.au/contact/

主要内容：报告：ETH、Tron和EOS占据了去年Dapp 98%的交易量；Ripple首席执行官再次强调无法控制XRP价格，再遭社区抨击；欧盟第5项反洗钱指令已正式生效，纳入加密服务提供商；硬件钱包多品牌产品遭淘宝集体下架；媒体：比特大陆AI团队裁员200余人，上百员工抱团拒签；中国证券报：区块链技术对金融行业的影响是天翻地覆的。 ETC Agharta硬分叉预计将于12日18点进行，仍有51.1%的节点未准备就绪etcnodes数据显示，按目前出块速度计算，ETC Agharta硬分叉时间约为2020年1月12日18：00。小葱查询数据发现，截至目前，48.9%的节点已准备就绪，51.1%的节点未准备就绪。 报告：ETH、Tron和EOS占据了去年Dapp 98%的交易量Dapp Review关于加密去中心化应用的新报告指出，2019年对dapp来说是个好年头，对Tron和ETH来说尤其好。报告指出，去年，Tron、EOS和Ethereum在dapp上积累了230亿美元的交易量，在此过程中，Tron超越了EOS，成为事实上的dapp娱乐网络。随着加密经济的发展，领先的智能合约网络所扮演的角色也发生了变化。Ethereum已经从ICO转向了defi, Tron已经成为了赌博应用领域最杰出的dapp，EOS己处于两者之间。在加密领域，Ethereum、Tron和EOS占据了dapp所有交易总量的98%。（bitcoin.com） 交易所CobinHood或将关闭，曾被质疑为“退出骗局”CobinHood在一封发给用户的通知中表示，它正在审计所有账户余额并迁移数据。它将于2020年2月10日重新开放。然后，交易所将向所有用户发送关于取款过程的电子邮件，然后允许用户取回他们的余额。与此同时，CobinHood还敦促用户不要进行存款。据悉，该交易所在开曼群岛注册，但总部设在中国台湾。据了解，去年年初，该交易所出售了母公司DEXON Foundation的DEXON代币，不到一个月就筹集了350万美元。后来，该公司在2019年5月申请破产。因此被投资者质疑为“退出骗局”。（CoinGape） Ripple首席执行官再次强调无法控制XRP价格，再遭社区抨击Ripple首席执行官Brad Garlinghouse在接受CNN的采访时再次强调，由于XRP的去中心化，Ripple无法控制XRP的价格。Brad的言论再次遭到社区抨击，加密货币分析师Tone Vays发推称：“我以前说过，以后还会说。Ripple声称他们的欺诈币XRP是去中心化和不可控的，但如果伊朗和朝鲜开始使用Ripple作为全球货币和价值转移方式，只需要美国当局打个电话给Garlinghouse，这个shitcoin就没了。” Kik再次请求法院审判美国SEC关于ICO一案的指控Kik(再次)请求在与美国SEC关于ICO一案的法律纠纷中接受审判，Kik希望对美国证券交易委员会(SEC)的指控进行审判，该委员会指控该公司在2017年的kin代币销售中进行了未经注册的证券发行。美国证券交易委员会周四提交了最新的诉讼进展情况，提供了初步的诉讼日程安排，并详细说明了双方安排其余部分作证的计划。（coindesk） Telegram称需要5至7周时间收集美国SEC所要求的代币销售相关信息Telegram表示需要五到七周时间来收集美国证券交易委员会（SEC）所要求其代币销售的有关信息。Telegram的律师事务所Skadden称，SEC的请求涵盖了12个国家和地区的770个个人和实体。而自9月以来Skadden只能审查76个实体，还需要更多时间来审查所有实体。(theblockcrypto) 欧盟第5项反洗钱指令已正式生效，纳入加密服务提供商欧盟第5项反洗钱指令（5AMLD）已于1月10日生效。5AMLD首次通过包括虚拟货币法币交易所或托管钱包提供商在内的加密服务提供商来扩大其监管范围。欧洲的加密货币公司正努力满足5AMLD提出的新监管准则。由于新法律要求了广泛的了解您的客户（KYC）和反洗钱（AML）程序，许多企业正在关闭。 硬件钱包多品牌产品遭淘宝集体下架比特派钱包发微博称，目前市场上所有品牌的区块链硬件钱包均已遭淘宝下架，包括BITHD、Cobo等品牌在内的产品均显示“宝贝不存在”、无法购买。此前，淘宝新增加了“区块链技术产品”二级类目，该类目下可以上架“带宽共享设备”和“数字货币硬件钱包”两类商品，即目前主流的数字加密货币硬件钱包可以在淘宝系统内上架销售。然而不到一个月的时间，此类产品便遭平台集体下架。 媒体：比特大陆AI团队裁员200余人，上百员工抱团拒签媒体向多位比特大陆相关业务线员工了解到，其AI团队将从360人裁到100人，从地域分布看，成都、武汉、上海和深圳的AI团队近乎“团灭”；从业务线看，100余人的服务器团队将被直接砍掉。同时，有200余名被裁员工因不满公司“N+1和期权，无承诺的13薪和保底年终奖”的赔偿方案，拉起维权群抱团拒签。但裁员指标和截止日期已定，公司以“现在不签，明天赔偿更少”相挟，无奈下签离职协议的员工越来越多。（星球日报） 中国证券报：区块链技术对金融行业的影响是天翻地覆的1月11日，中国证券报刊文“人工智能和区块链重塑未来金融形态”。文章表示，区块链技术对金融行业的影响是天翻地覆的。首先，在金融交易数据方面，存放在区块链系统中的数据安全性更高，区块链技术本身能够有效保证交易数据的安全性和真实性。区块链技术去中心化的特征，可以使数据更加透明，从根本上解决大量数据在第三方金融机构集中和形成信息孤岛的问题。其次，区块链技术本身不仅能够实现数据信息的永久性存储，而且能够通过对数据增加附加信息来实现数据信息归属的标识和产权的确认，这种机制能够有效地解决大数据共享与隐私保护之间的内在矛盾。这意味着每个个体都可以拥有自己的数据资产，这些数据资产同样可以带来相应的信用和其他衍生价值。最后，区块链技术依赖程序算法，实现公开透明的交易规则，使所有参与节点能够自动运行，共同维护，共同进行信用支撑，打破传统金融体制中的精英垄断，使民众广泛参与发展普惠金融。 央行：基本完成法定数字货币顶层设计、标准制定、功能研发、联调测试等工作央行发文《盘点央行的2019金融科技》。文中称，央行在坚持双层运营、M0替代、可匿名的前提下，基本完成法定数字货币顶层设计、标准制定、功能研发、联调测试等工作。扎实开展数字货币研究，跟踪研究数字货币国际前沿信息。

Izgalmasan indult a nap, az előző esti céges karácsonyozás azonban áldozatokat szedett, így csak egy ember jelent meg a stábból :) Aztán megérkezett az utánpótlás is, tisztelet a hősöknek. Lapszemle és piaci összefoglaló után budapesti közlekedéssel foglalkoztunk. Sok éve lassan, de megállíthatóan csurdogáló folyamatokról beszélt Andó Gergely, a Közlekedésvilág lapcsoport lapigazgatója az M0-ás körgyűrű befejezése és a ferihegyi vasútvonal kapcsán. Aztán: minden, amit nem tudtál az ittas vezetésről - itt a céges bulik, karácsony, összejövetelek és szilveszteri partik ideje. De akár egy sütitől vagy szaloncukortól is jelezhet a szonda! Lőrik József, ügyvéd mondta el, mire kell figyelni. Mi várható 2020 ingatlanpiacán? Benedikt Károly, a Duna House Marketing és PR vezetője vetítette előre.

Egy Prima díjjal gazdagabban ültünk be a stúdióba, és köszöntük meg a közönségnek. Majdnem sikerült kihagyni a Natáliákat, de végül felköszöntöttük őket is. Budapest rovatunkban volt szó vonatokról, M0-sról, meg a lajhárbébiről, közszolgálati stílusban. Alaposabban körbejártuk az MNB-kötvényprogramját is. A magyar vállalati kötvénypiac nem volt éppen túl élénk, ezért is volt jó ötlet a felélesztésére tett kísérlet. De vajon azzal, hogy az MNB veszi meg a papírok egy részét és ezzel kiemelkedő kockázatot vállal, jó megoldás született-e? Kasnyik Márton, a g7.hu főszerkesztője válaszolt. Magyar inflációs adat, amerikai és eurózónás kamatdöntés várható a héten, Tardos Gergely, az OTP Elemzési Központ vezetője mondta el, mire számít. Masszív büntit kap a Facebook, megbeszéltük az ügy hátterét.

内容来源：2019年10月30日，在博石教育集团主办的博石·标杆微课堂上，前阿里巴巴集团事务部大政委陈亮进行了题为“聊聊阿里政委的那些事儿”的精彩分享。笔记侠作为合作方，经主办方及讲者审阅，授权发布。作者简介：陈亮，前阿里巴巴集团事务部大政委阿里巴巴能发展到如此大的规模，很大一部分原因是存在“政委体系”。那么，政委在阿里扮演什么样的角色呢？下面我们从个体层面和团队层面分别来看。在个体层面，政委主要负责四个方面：第一，提供员工关怀。第二，给员工进行职业生涯规划。第三，同步公司信息。第四，倡导价值观跟坚守底线。第一，提供员工关怀。阿里在最早的B2B时期，全国有二十六、七个大区，绝大部分是以销售为主的团队。分公司里的人员分三层，分别是区域经理、主管、员工。区域经理和主管大多时候将注意力放在业务层面，对于人员的成长和关怀参差不齐。还有一个情况，当时阿里几乎所有的中国供应商直销团队都是异地招聘过来的。他们在进阿里之前可能从来没有离开过当地，或者从来没有到过浙江工作。对于这些人来说，首先要能够在当地生活，这个时候就需要政委在生活上对他们予以照顾。同时，阿里早期在打造销售团队的时候，是统一租房住宿。HR或者政委会去帮助这些员工找到合适的住房，让几个团队住在一起，方便沟通交流，也方便管理。第二，进行职业生涯规划。当然不是简单地帮员工规划职业生涯，而是让员工的成长过程对未来的发展有所帮助。阿里当年做的事情，今天很多公司也在做，就是实行双轨制的发展。员工成长有P线和M线，P线是专业路线，P14就是副总裁级别的销售。我们需要去看哪些人适合做管理，哪些人不太适合做管理，始终让他们走在正确发展的道路上。第三，公司信息的同步。阿里从最早做直销团队开始，就面临怎么激发个体、让员工有安全感的问题。由于业务leader的关注点主要是如何驱动业务，有时候会屏蔽掉一些信息。所以我们要避免所有信息都来自于业务的leader，而是需要阿里的政委将公司的部分信息同步给员工，让员工对组织了解得更透彻一些，让他们感到踏实，在工作过程中获得安全感。这是让员工拥有安全感很重要的来源之一。第四，倡导价值观跟坚守底线。阿里的HR和政委很重要的任务就是倡导价值观。价值观，说白了就是扬善，就是希望组织成员通过什么样的方式来拿到结果。比如说什么样的行为是我们倡导的，什么样的行为是我们反对的。去见客户的时候，应该是什么样的状态，怎么跟客户沟通等等。还有很重要一点，哪些现实是我们不能够去突破的，我们称之为底线的坚守。阿里很重要的底线是不能作假。你可以做不到，但是不能作假。举个例子，阿里每季度都会对销售人员进行业务知识和专业知识考试，考不及格可以补考，补考再不及格会有一些小小的惩罚，或者是一些处分之类的，不管怎样都可以继续留下来工作。但是如果在这两次考试当中，只要有一次作弊被抓到就要被开除掉。作为政委，你必须要坚守底线。因为很多时候，你要开掉的这些考试作弊的人，有可能业绩很好。但是没办法，必须要坚守组织价值观的底线。在团队层面，政委主要负责四个方面：第一，招聘。第二，干部梯队的搭建。第三，沟通机制的建立。第四，团队文化建设。第一，招聘。政委和招聘专员的区别是Why和How之间的差异。招聘专员的出发点是把人招到，而政委的出发点是怎样能够让业务有人来做，视角上其实有很大的差别。比如说，如果三个月招不到人，招聘专员会更多从拓展招聘渠道考虑，而政委更多考虑的是从业务出发，要跟业务团队分析招不到人对组织的影响，有没有可能调整一些业务的逻辑结构，或者去找到相对来讲综合能力要求没那么高的人，或者突破原有的薪资架构等方式来解决问题。其实招聘是解决业务没有人做的最后方式，但是绝大部分的业务团队都会把招聘变成解决业务没有人做的第一方式。作为政委来讲，帮助业务团队成长很重要的一点是怎样去切入，让业务在当下能够完成，同时又能够可持续发展。第二，干部梯队的搭建。对于业务leader来讲，培养人一定是很重要的一份工作，只是很多时候把这份权利给剥夺了。M0计划就是去寻找一些潜在的管理者，我们建立了接班人机制，或者叫做找到业务的backup（后援）。每个业务团队的leader，都必须要给自己找到继任者，甚至如果找不到继任者就不能晋升。寻找接班人是管理者在组织上的第一要务。如果每个岗位都能给自己找到接班人，团队的管理者其实就不缺了。让组织中不断有人持续成长，这是作为管理者非常重要和核心的工作。对一线管理者的训练比培训更有效果、更有价值。一线的管理者，需要给他制造不同的业务场景来进行训练。比如接班人计划就是很好的业务场景，教学相长，教是最好的学习，所以通过对接班人的指导和辅导，管理者自身也能有很大的成长。第三，沟通机制的建立。阿里的沟通机制非常有意思，叫one over one plus HR，就是反馈问题的机制。员工怎样把一线的声音反馈到上面来？以前我们有各种各样的方式，比如员工信箱、定期圆桌会议等等，但是始终不能保证反馈机制是有效的。阿里的one over one plus HR，举个例，比如对于绩效考核的结果，如果你不满意，第一去找的一定是你的直接上级。你的上级听了以后，可能会有两种反应，一种是他觉得确实他做错了，去改，那在上级这条线上就结束了。还有一种可能上级觉得是对的，你们之间的认知有分歧。你要继续往上反馈的话，必须事先告知你的上级，同时你要去带上政委。这样的机制我们称之为“化阴谋为阳谋”，能够保证组织当中永远是开放的状态。管理要有力量，一定是从上至下的力量足够强大，也就是充分信任每一层级的管理者。但同时要防止推卸责任，保证one over one plus HR的机制是顺畅的。这样的组织相对来讲才是比较公开透明，同时又能够兼顾效率和执行力的组织。第四，团队文化建设。一说到团建，绝大部分人就会觉得就是吃饭、K歌、烧烤或者旅行等等。这些是团建中很重要的组成部分，跟生活相关，把人聚在一起，是聚人气的团建，生活的团建。除此之外，还有思想的团建、目标的团建。这两个其实才是团建的最高境界，特别是目标的团建。对于阿里、淘宝来讲，最大的团建就是每年的双十一，能够帮助整个组织增加战斗力；对于直销来讲，最大的团建就是每年12月的业务竞赛。如何像设计一次团队建设一样去设计活动，是团建的最高境界。本期编辑：智勇 审稿及主播：晴天

Martin Chorzempa, research fellow the Peterson Institute, and Dovey Wan, founding partner at Primitive Ventures, discuss China's new blockchain push and the forthcoming DCEP. They cover how the blockchain initiative is part of an effort to set global blockchain standards, how it fits into the larger U.S.-China trade war as well as the threat from Facebook's Libra, and why part of the motivation behind the DCEP may stem from the shadow banking system in China. They also talk about how the DCEP might work, why it aims to be like cash, and ways in which a successful digital currency could be used to help internationalize the renminbi, but why other countries will likely still resist becoming more dependent on China's currency. We also explore what "controlled anonymity" will look like in the DCEP, why it might actually be preferable to transacting via WeChat Pay or Alipay and whether or not Chinese people will become interested in Bitcoin due to this exposure to blockchain technology. Thank you to our sponsors!  Kraken: https://kraken.com/ Crypto.com: https://crypto.com/ CipherTrace: http://ciphertrace.com/unchained Episode links:  Martin Chorzempa: https://www.piie.com/experts/senior-research-staff/martin-chorzempa https://twitter.com/ChorzempaMartin Dovey Wan: https://twitter.com/DoveyWan Xi Jinping’s speech: https://www.coindesk.com/president-xi-says-china-should-seize-opportunity-to-adopt-blockchain Cryptography law: https://www.coindesk.com/chinas-congress-passes-cryptography-law-effective-jan-1-2020  China’s 500 enterprise blockchain projects: https://www.coindesk.com/from-banking-giants-to-tech-darlings-china-reveals-over-500-enterprise-blockchain-projects Changchun Mu, the deputy director of the payment and settlement department of the PBOC, on how DC/EP aims to replace the M0 money supply (banknotes and coins): http://www.cf40.org.cn/uploads/newsletter/20190803.pdf Dovey’s article on how the digital yuan will affect the M0 money supply: https://www.coindesk.com/digital-renminbi-a-fiat-coin-to-make-m0-great-again China’s already very digital economy: https://www.piie.com/blogs/realtime-economic-issues-watch/who-likes-facebooks-libra-currency-not-chinese Reaction of Chinese dissident to China’s blockchain push: https://www.coindesk.com/bitcoin-dissident-sees-dark-warnings-in-chinas-blockchain-push Unconfirmed interview with Alex Gladstein of the Human Rights Foundation: https://unchainedpodcast.com/why-the-digital-yuan-could-one-day-be-seen-as-a-blunder/ The commercial entities involved in helping to release the DCEP: https://www.forbes.com/sites/michaeldelcastillo/2019/08/27/alibaba-tencent-five-others-to-recieve-first-chinese-government-cryptocurrency/#95e9d351a516 How they will be involved: https://twitter.com/DoveyWan/status/1191807688570626048?s=20 ”Controlled anonymity“: https://twitter.com/ChorzempaMartin/status/1162071943568338944?s=20 Problems that could arise with the DCEP: https://www.scmp.com/economy/china-economy/article/3035797/blockchain-endorsement-chinas-xi-jinping-could-lead-fraud-and People with poor social credit banned from buying plane and train tickets: https://www.theguardian.com/world/2019/mar/01/china-bans-23m-discredited-citizens-from-buying-travel-tickets-social-credit-system The FT on why China’s currency will not replace the USD: https://ftalphaville.ft.com/2018/09/19/1537329600000/China-s-currency-will-not-replace-the-US-dollar/  2000 speech by Bill Clinton: https://archive.nytimes.com/www.nytimes.com/library/world/asia/030900clinton-china-text.html?mcubz=2&module=inline Change in plans to eliminate the Bitcoin mining industry: https://www.coindesk.com/sichuan-should-work-to-remain-attractive-to-crypto-mining-policy-advisor

Show support appreciated: 35iDYDYqRdN2x6KGcpdV2W1Hy3AjGje9oL Matthew updates on the Crypto Voices Monetary Base exhibit for 2019 Q3. This episode will be a lot easier if following along with the tweet thread, which is here: https://twitter.com/crypto_voices/status/1191723457467355137?s=20 Or, you can also follow along with the exhibits here: cryptovoices.com/basemoney Bottom line: Bitcoin is currently the #9th largest base money in the fiat world. Bitcoin is currently the #11th largest base money in the fiat world, including past base monies gold & silver. Bitcoin is unquestionably unlike anything else in the (financial) world. However, if you are going to try and compare Bitcoin's supply with other supply curves in the financial world, don't. The *only* money supply you can compare it to is fiat's "Monetary Base," or "Base Money." Firstly, something needs to be used as a medium of exchange to technically be called "money." Gold and silver used to be. Fiat is now. Bitcoin very well could be. But don't get carried away. We need to compare bitcoin (and gold... and silver) to fiat's "base money" supply, and *only* to the base money supply. M1/M2/M3 and all others simply aren't comparable. Why? Because those supplies include "claims" on base money. In this episode, we go deeper on two new charts: 1) central bank gold reserves versus their monetary base; 2) the world basic money supply compared to the world bank money supply (M3, less M0). Remember, M0 is the cash and coin that is physically in circulation, AND outside of bank vaults. Listen on to learn more. Links for more info: cryptovoices.com/basemoney Hosts: Matthew Mežinskis, Fernando Ulrich Music: New Friend Music newfriendmusic.com/ Site: cryptovoices.com/ Podcast & Information Cryptoeconomics & Liberty Thanks for listening! Show content is not investment advice in any way.

Thanks to Stevo the Gutter Nerd, WhittleHill, and dawgsup for the recent reviews!Zach and Orey start a new (un)Characteristic tradition by creating a character based on a suggestion from last week’s guest.M0-037 is feeling some big feels as he watches his cyborg half brother take his final breaths. Too bad his lingual centers aren’t advanced enough to portray emotion.Rate and review (un)Characteristic for a chance to win our new Character List T-Shirt! Screencap your review and send it to uncharacteristicshow@gmail.com for a chance to win! WE HAVE MERCH! Coffee mugs, shirts, stickers, phone cases, and even FANCYBOI FRAMED PRINTS.Send your prompts to uncharacteristicshow@gmail.com for a chance to be part of our (un)iverse!@theuncharacters@whatwouldoreydo@whackyzach

Welcome to Finance and Fury, the Furious Friday edition! I’ve been thinking a lot about what we are taught in economics, the basic ‘101’. Specifically, if you print a lot of money you get hyper-inflation. There are plenty of stories to back this up Germany Weimar republic, and Venezuela right now – there are plenty of countries with hyperinflation Central banks around the world (and at home) are trying for more inflation, and have increased their money supply over time. But we’re ending up with lowering inflation. This is puzzling on the surface, though it has a pretty simple answer. Inflation and CPI – What we’re told they are - quantitative measure of the rate at which the average price level of a basket of selected goods and services in an economy increases over a period of time. Rise in the level of prices – why a $1 today is worth more than $1 in 1 year, let alone 100 years CPI is what is used to measure the basket of goods RBA monetary policy – Try to keep between 2-3% inflation through influence on money supply. The issue with percentage targets is Compounding Compounding is a very powerful tool, it can be your friend or your foe, it really depends what is compounding – Returns (growth), interest, or inflation Returns – for an Investor who owns assets or cash, it’s good. Interest – if you owe money it’s bad Inflation – for an Investor or individuals/consumers it’s bad, but if you owe money it’s actually very good Inflation is bad for us – especially when it’s compounding and is controlled. We want things to be cheaper. But unless our wages keep up (which is determined by the economy) we suffer pricing squeezes. Plus, unless you have massive amounts of debt your savings and investments give lower real returns. This is why inflation is great for Governments! If you have no real assets but are cash rich from income each year from tax payers – You need to either budget well or borrow for funding shortfalls – Every nation in the G20 is in debt – to who? Debt goes one level further in relationship to currency/fiat monetary system – When you get shut off (ex-communicated) – nobody will buy the debt off you to print money – currency collapse – creates additional inflation due to the relative cost of imported goods Can cripple a country that has their debt valued in another currency – impossible to pay back Example - Germany with war reparations - Gold or other peoples’ currencies Crippled them – First - Currency is backed to your supply of gold back then – so lost supply of what backed currency If you have to pay reparations in someone else’s currency, or give up your gold supply that is backing your currency, what will happen to the price? Today – IMF is the bail out bank for nations – But bail them out in debt based on USD International debt (government or private bonds) dates back a way – The 5 Rothschild brothers (Salomon – Austria, Nathan – England, Calmann – Italy, Jacob – France, Amschel – Germany) opened their banks up to international markets – increasing connectivity through lending capacity across boarders – Governments of the day welcomed it Quote – Revolutions are generally triggered of by deficiency of money. By preventing such deficiencies, the Rothchild system may serve to preserve peace in Europe. This system or rather Nathan Rothschild its inventor is still providing for such peace. It does not inhibit one state from making war on another exactly as before, but it does make it difficult for people to overthrow the established authority.” - Heinrich Heine – German Journalist wrote in 1830– he goes on for a while, gets deep about how religion can be replaced by money. Unfortunately, though – as this system grew, the magnitude of war exponentially increased – whoever has the most money in war wins – most kingdoms of the past eventually ran out when fighting prolonged wars But still faced a problem. These bonds were valued in Sterling which in turn was backed by gold, while there was an increase in money supply from fractal banking reserve – still limited to the finite level of gold/sterling to back it. There was almost no inflation under the gold standard – debts had to be paid – no inflating them away   But the biggest debtors were the Governments of the day (mostly monarchy’s) Napoleonic war 1815 – almost £10 million pounds lent out Rebuild - 1818 £5 million loan to the Prussiangovernment and the issuing of bonds for government loans- collateral Continued on like that until Governments got their own way of producing funding Had central banks already – but still limited by gold. Not anymore, they print as much as they want   Theory of money supply Increase money, you get inflation. It makes sense – the more of something you have the less valuable it is Inflation – devalue of the dollar in real terms - $100 stays $100 – but can’t buy as much (hidden tax) Why don’t we see this today? Money supply has increased massively since we went to the Fiat system – to achieve the target of 2.5% p.a. M0: includes bank reserves, so M0 is referred to as the monetary base, or narrow money. M3: M1 Money base plus substitutes (M2) plus large and long-term deposits. Money Supply – M0 – 2000 – 30bn – 2019 – 110bn – 7.5% growth p.a. - M3 – 400bn to 2.2trn over same time – 10% p.a. Very consistent – looking back to 1976 - around when we started adopting Fiat – been 10% growth p.a. Comparing Inflation over this time – 2.4% since 2000 – been trending down – since 1975 – peak of 16% - trend down to 1.8% - RBA done well to keep it within the band of around 2.5% since late 1990s when it was introduced. Thanks to the interconnective nature of the monetary system there’s no shortages of banks and governments willing to demand the level of debt, bonds to meet the increased supply of money. But also, this gets directed into ‘hard asset prices’ and compounds the price of everything massively. Property prices, due to every increasing borrowing capacity. As the flow on effect of money supply is that you have low interest – at least this supply/demand relationship seems to work. In the past – before early 90s inflation got a bit wild – some years it was up. Why are the same things tried over and over again, does this go on and on with a different result? Imagine that you put your whole life into a theory/assumption – how easy is it to admit you are wrong when presented with new/conflicting evidence? If you can be paid Not when you make money off teaching that theory based around expertise But now imagine that a new theory came out, or you ignored evidence that contradicted major assumptions – and one of your students wanted to write their thesis on this – never get accepted What happens when over a 70-year period this cycle continues – the same theory is incentivised to be regurgitated regardless of if it outdated A lot of economic theory is based around a world without globalisation and instant transactions, some even electricity – no wonder the models have a hard time predicting if they cant adapt Dad Joke – What do economists and Major League baseball hitters have in common? Both get paid regardless of if they strike out 70% of the time. But those declines were correction years to help with affordability and the large increased were normally due to an economic shock – like a WW.  Where an average target is dangerous if back testing data to fit a model (talked about in last ep)  What average would you prefer as a return 10% or 5% average? 10% obviously – but what if now – prob of 50/50 either 20%, or 0%, versus compounding of 10% - compounding of 10% every day – Sometimes you might want the scenario of an average of 5% over 10% Took an average rate as a target that worked well when the economy was growing – but this was back testing And neglected to look at the importance of corrections – price drops/low inflation Example – low inflation when Rockefeller (Standard Oil) flooded the market with cheap oil – and saved the whales (unintended consequence) – This was a massive benefit to any countries lucky to participate in this early through having free markets to adopt this technology – Issue with inflation – doesn’t just create a strain on household spending if wage growth cant also keep up   Business side of things – Their prices are what inflation measures - Are businesses borrowing? Not so much here - Inflation in their costs of inputs – Not from money supply but increased regulations and taxes Taxes – like GST – companies had to put up their prices by 10% - companies do get to claim back some of the GST on expenses – but not on all expenses – like wages – instead they not only cover the PAYG for the employee, but also pay around 4-5% depending on state in tax on wages if they are paying their employees too much Creates an artificial strain on businesses to keep up with increasing costs of their own while not being able to pay additional costs of employing people – there is nothing wrong with high inflation – as long as it can be allowed to correct and that the inflation being outstripped by wage growth – coming from company profits Where has the money been going? What isn’t measured by CPI – Hard asset price increases – property, shares, etc. e. inflated hard asset prices through compounding growth – from increase of money supply - Why is inflation good? The Government – who else can borrow billions of dollars at low rates and let inflation eat away repayments? No need for fiscal restraint if you can let inflation eat away your debt on a 70 year bond. At 2.5% $1bn turns to $177m over that time – interest is covered by tax payers – or another bond But with money supply going up and up in ‘uncollateralised debt’ – Governments may not be able to afford the increased interest repayments if rates do go back up What the target does is switch the old models from a simple interest outcome, to a compounding one – has drastic exponential factors the longer it goes on Analogy of after big night of drinking – Wake up and on the verge of a hangover I’ll admit there has been one or two times I have woken up hungover and kept drinking What happens the next day when the party is over? Hangover is worse than normal – We should have had a hangover by now – there is a backup plan the IMF is looking into to increase global inflation – trying to escape the true horrors of a 2 day hangover, or in this case debt collapse How to avoid a hangover from a credit crunch? Work towards that answer in the next FF ep.   https://www.rba.gov.au/education/resources/explainers/inflation-and-its-measurement.html       https://www.abs.gov.au/websitedbs/d3310114.nsf/home/abs+chief+economist+-+70+years+of+inflation+in+australia

Consensus or Controversy? Clinical Investigators Provide Perspectives on the Current and Future Management of Prostate Cancer — Part 2: Our one-on-one interview with Dr Smith featuring emerging research and cases from his practice. Recent advances in the treatment of nonmetastatic CRPC (00:00) Effect of PSA doubling time on prognosis for patients with nonmetastatic disease (3:01) PSA doubling time and clinical decision-making for patients with M0 disease (7:59) Counseling patients with nonmetastatic disease about goals of therapy and expected side effects (10:26) Similarities and differences in the design, entry criteria and efficacy endpoints among the ARAMIS, SPARTAN and PROSPER trials (13:25) Comparison of the side-effect profiles of apalutamide, enzalutamide and darolutamide (15:35) Counseling patients receiving long-term ADT about treatment-related fatigue (18:35) Comparison of primary (metastasis-free survival) and secondary outcomes among the ARAMIS, SPARTAN and PROSPER trials (20:32) Choosing among darolutamide, apalutamide and enzalutamide (22:45) SPARTAN trial: PFS2 improvement with apalutamide for high-risk nonmetastatic CRPC (24:42) Outcomes, tolerability and appropriate use of abiraterone in combination with prednisone (26:27) Similarities and differences in the design, entry criteria and efficacy endpoints between the LATITUDE (ADT with abiraterone/prednisone or placebo) and ARCHES (ADT with enzalutamide or placebo) trials for patients with metastatic HSPC (29:46) Key clinical and practical factors guiding the selection of docetaxel versus abiraterone/prednisone for metastatic HSPC (35:39) Perspective on the intensification of therapy for patients with metastatic HSPC and suboptimal responses to ADT (39:08) Spectrum and frequency of somatic and germline DNA repair gene mutations in prostate cancer; activity of PARP inhibitors in patients with metastatic CRPC (40:57) Incidence of MSI-H/dMMR molecular phenotype in patients with prostate cancer; indications for testing and current role of immune checkpoint inhibitors (46:37) Results of a Phase II prospective trial of lutetium-177-PSMA-617 theranostics in metastatic CRPC (50:42) Novel immune checkpoint inhibitor-based combinations for metastatic CRPC (56:08)   Select publications

Go online to PeerView.com/XHP860 to view the entire program with slides. In this activity, experts in the management of patients with prostate cancer discuss recent advances that have rapidly expanded the therapeutic landscape, including treatments for both early-stage and advanced disease. Focusing on selection and sequencing of therapies based on patient and tumor characteristics, prior treatment history, and patient preferences, the expert panel provides an engaging MasterClass and Practicum that combines key clinical evidence and current guideline recommendations with practical guidance for personalizing application of approved and investigational therapies throughout the prostate cancer disease continuum, including nonmetastatic (M0), metastatic hormone-sensitive, and metastatic castration-resistant settings. Upon completion of this activity, participants should be better able to: Evaluate the efficacy, safety, and clinical role of approved and investigational therapies, including hormone, cytotoxic, immuno-oncology, bone-directed, and molecularly targeted therapies alone or in combination for localized, M0, and advanced prostate cancer, Assess current clinical trials evaluating agents with varying modalities alone or in combination and refer appropriate patients with prostate cancer for clinical trial enrollment, Recommend individualized treatment plans for patients with prostate cancer throughout the disease continuum in accordance with current clinical guidelines, expert recommendations, disease and patient characteristics, and patient needs/preferences.

Go online to PeerView.com/XHP860 to view the entire program with slides. In this activity, experts in the management of patients with prostate cancer discuss recent advances that have rapidly expanded the therapeutic landscape, including treatments for both early-stage and advanced disease. Focusing on selection and sequencing of therapies based on patient and tumor characteristics, prior treatment history, and patient preferences, the expert panel provides an engaging MasterClass and Practicum that combines key clinical evidence and current guideline recommendations with practical guidance for personalizing application of approved and investigational therapies throughout the prostate cancer disease continuum, including nonmetastatic (M0), metastatic hormone-sensitive, and metastatic castration-resistant settings. Upon completion of this activity, participants should be better able to: Evaluate the efficacy, safety, and clinical role of approved and investigational therapies, including hormone, cytotoxic, immuno-oncology, bone-directed, and molecularly targeted therapies alone or in combination for localized, M0, and advanced prostate cancer, Assess current clinical trials evaluating agents with varying modalities alone or in combination and refer appropriate patients with prostate cancer for clinical trial enrollment, Recommend individualized treatment plans for patients with prostate cancer throughout the disease continuum in accordance with current clinical guidelines, expert recommendations, disease and patient characteristics, and patient needs/preferences.

Go online to PeerView.com/XHP860 to view the entire program with slides. In this activity, experts in the management of patients with prostate cancer discuss recent advances that have rapidly expanded the therapeutic landscape, including treatments for both early-stage and advanced disease. Focusing on selection and sequencing of therapies based on patient and tumor characteristics, prior treatment history, and patient preferences, the expert panel provides an engaging MasterClass and Practicum that combines key clinical evidence and current guideline recommendations with practical guidance for personalizing application of approved and investigational therapies throughout the prostate cancer disease continuum, including nonmetastatic (M0), metastatic hormone-sensitive, and metastatic castration-resistant settings. Upon completion of this activity, participants should be better able to: Evaluate the efficacy, safety, and clinical role of approved and investigational therapies, including hormone, cytotoxic, immuno-oncology, bone-directed, and molecularly targeted therapies alone or in combination for localized, M0, and advanced prostate cancer, Assess current clinical trials evaluating agents with varying modalities alone or in combination and refer appropriate patients with prostate cancer for clinical trial enrollment, Recommend individualized treatment plans for patients with prostate cancer throughout the disease continuum in accordance with current clinical guidelines, expert recommendations, disease and patient characteristics, and patient needs/preferences.

Go online to PeerView.com/XHP860 to view the entire program with slides. In this activity, experts in the management of patients with prostate cancer discuss recent advances that have rapidly expanded the therapeutic landscape, including treatments for both early-stage and advanced disease. Focusing on selection and sequencing of therapies based on patient and tumor characteristics, prior treatment history, and patient preferences, the expert panel provides an engaging MasterClass and Practicum that combines key clinical evidence and current guideline recommendations with practical guidance for personalizing application of approved and investigational therapies throughout the prostate cancer disease continuum, including nonmetastatic (M0), metastatic hormone-sensitive, and metastatic castration-resistant settings. Upon completion of this activity, participants should be better able to: Evaluate the efficacy, safety, and clinical role of approved and investigational therapies, including hormone, cytotoxic, immuno-oncology, bone-directed, and molecularly targeted therapies alone or in combination for localized, M0, and advanced prostate cancer, Assess current clinical trials evaluating agents with varying modalities alone or in combination and refer appropriate patients with prostate cancer for clinical trial enrollment, Recommend individualized treatment plans for patients with prostate cancer throughout the disease continuum in accordance with current clinical guidelines, expert recommendations, disease and patient characteristics, and patient needs/preferences.

Go online to PeerView.com/XHP860 to view the entire program with slides. In this activity, experts in the management of patients with prostate cancer discuss recent advances that have rapidly expanded the therapeutic landscape, including treatments for both early-stage and advanced disease. Focusing on selection and sequencing of therapies based on patient and tumor characteristics, prior treatment history, and patient preferences, the expert panel provides an engaging MasterClass and Practicum that combines key clinical evidence and current guideline recommendations with practical guidance for personalizing application of approved and investigational therapies throughout the prostate cancer disease continuum, including nonmetastatic (M0), metastatic hormone-sensitive, and metastatic castration-resistant settings. Upon completion of this activity, participants should be better able to: Evaluate the efficacy, safety, and clinical role of approved and investigational therapies, including hormone, cytotoxic, immuno-oncology, bone-directed, and molecularly targeted therapies alone or in combination for localized, M0, and advanced prostate cancer, Assess current clinical trials evaluating agents with varying modalities alone or in combination and refer appropriate patients with prostate cancer for clinical trial enrollment, Recommend individualized treatment plans for patients with prostate cancer throughout the disease continuum in accordance with current clinical guidelines, expert recommendations, disease and patient characteristics, and patient needs/preferences.

Go online to PeerView.com/XHP860 to view the entire program with slides. In this activity, experts in the management of patients with prostate cancer discuss recent advances that have rapidly expanded the therapeutic landscape, including treatments for both early-stage and advanced disease. Focusing on selection and sequencing of therapies based on patient and tumor characteristics, prior treatment history, and patient preferences, the expert panel provides an engaging MasterClass and Practicum that combines key clinical evidence and current guideline recommendations with practical guidance for personalizing application of approved and investigational therapies throughout the prostate cancer disease continuum, including nonmetastatic (M0), metastatic hormone-sensitive, and metastatic castration-resistant settings. Upon completion of this activity, participants should be better able to: Evaluate the efficacy, safety, and clinical role of approved and investigational therapies, including hormone, cytotoxic, immuno-oncology, bone-directed, and molecularly targeted therapies alone or in combination for localized, M0, and advanced prostate cancer, Assess current clinical trials evaluating agents with varying modalities alone or in combination and refer appropriate patients with prostate cancer for clinical trial enrollment, Recommend individualized treatment plans for patients with prostate cancer throughout the disease continuum in accordance with current clinical guidelines, expert recommendations, disease and patient characteristics, and patient needs/preferences.

To show and share your project at 7:30pm today, view the chat or in discord https://adafru.it/discord and look for the JOIN link to join the Google Hangout On Air. For best results be on a wired connection and have a headset and mic! Visit the Adafruit shop online - http://www.adafruit.com ----------------------------------------- LIVE CHAT IS HERE! http://adafru.it/discord Adafruit on Instagram: https://www.instagram.com/adafruit Subscribe to Adafruit on YouTube: http://adafru.it/subscribe Join our weekly Show & Tell on G+ Hangouts On Air: http://adafru.it/showtell New tutorials on the Adafruit Learning System: http://learn.adafruit.com/ ----------------------------------------- John Park @0:57 Bluetooth Rover Noe & Pedro @2:23 3D printed Pi Stand Erin @3:31 LED Spats and LED fascinators Kattni @5:55 VCNL code for light and proximity sensor Scott @9:10 Yamaha synthesizer PCBs Melissa @11:20 and @15:11 Grand Central controlled robot Sophy @12:20 Astro helmet with its bitsy M0 and LEDs Lucian @17:09 single purpose user device for creative writing TG-Techie @22:05 shapes Roberto @23:28 Freddie Mercury cosplay and 3D printed earrings Dan @25:26 wink calendar and name badge

Dj Jim представляет еженедельное радио-шоу "ElectroSpeed"! В ночь со вторника на среду с 1 до 2 слушай на Dfm. II DjJim.RU II iTunes II ВКонтакте II FaceBook II Twitter II Instagram II Mixcloud II SoundCloud II Программа выходит с 2008 года. Если вы хотите получать записи эфиров для еженедельной ротации на вашей интернет или FM радиостанции, вам сюда: djjim.ru/radioshow 0:00 Tom Staar & Eddie Thoneick - Otherside 2:57 Kato - Motions (Kato Remix) 5:04 Yves Larock Feat. Rahiz - I Know (Larock Dub Rework) 8:08 Jay Hardway - Let Me Tell You Something 10:49 Ron Reeser - Runaground 14:19 Holl & Rush x Raven & Kreyn feat. Ryan Konline - Faith 17:01 Semitoo - We Own the Night 20:05 Maximals - I Got It (Boothed & Etta Matters Remix) 23:22 Breathe Carolina x Lucas & Steve x Sunstars - Do It Right 26:05 Chocolate Puma & Carta feat. Kris Kiss - Bump 28:32 DNF x David Puentez - Put Your Hands Up 29:46 MusicbyLukas x Mastrovita - Hold On 32:59 Exodus Feat. Brielle Von Hugel - Tightrope 35:44 Sagan - BOY 39:03 M0 & Diplo - Sun In Our Eyes (Don Diablo Remix) 42:22 Promise Land - Loving You 46:03 Tong Apollo & Nicole Chen feat. I Am ASA - The Sound Of Ocean 47:34 Tiesto - WOW 49:17 Jaycen A'mour - That Sound 51:48 Ofenbach feat. Benjamin Ingrosso - Paradise (Alex Shik Remix) 55:21 Exodus & Saladin - Got My Body 58:32 Alessia Cara - Growing Pains (Toby Green Remix)

Dj Jim представляет еженедельное радио-шоу "ElectroSpeed"! В ночь со вторника на среду с 1 до 2 слушай на Dfm. II DjJim.RU II iTunes II ВКонтакте II FaceBook II Twitter II Instagram II Mixcloud II SoundCloud II Программа выходит с 2008 года. Если вы хотите получать записи эфиров для еженедельной ротации на вашей интернет или FM радиостанции, вам сюда: djjim.ru/radioshow 0:00 Tom Staar & Eddie Thoneick - Otherside 2:57 Kato - Motions (Kato Remix) 5:04 Yves Larock Feat. Rahiz - I Know (Larock Dub Rework) 8:08 Jay Hardway - Let Me Tell You Something 10:49 Ron Reeser - Runaground 14:19 Holl & Rush x Raven & Kreyn feat. Ryan Konline - Faith 17:01 Semitoo - We Own the Night 20:05 Maximals - I Got It (Boothed & Etta Matters Remix) 23:22 Breathe Carolina x Lucas & Steve x Sunstars - Do It Right 26:05 Chocolate Puma & Carta feat. Kris Kiss - Bump 28:32 DNF x David Puentez - Put Your Hands Up 29:46 MusicbyLukas x Mastrovita - Hold On 32:59 Exodus Feat. Brielle Von Hugel - Tightrope 35:44 Sagan - BOY 39:03 M0 & Diplo - Sun In Our Eyes (Don Diablo Remix) 42:22 Promise Land - Loving You 46:03 Tong Apollo & Nicole Chen feat. I Am ASA - The Sound Of Ocean 47:34 Tiesto - WOW 49:17 Jaycen A'mour - That Sound 51:48 Ofenbach feat. Benjamin Ingrosso - Paradise (Alex Shik Remix) 55:21 Exodus & Saladin - Got My Body 58:32 Alessia Cara - Growing Pains (Toby Green Remix)

This podcast is a Q&A session providing more information on questions engineers may have about the Tiny Gecko Series 1 (EFM32TG11) Top 3 benefits to Engineers Low Energy LCD Driver CAN Peripheral support Tiny Gecko in wireless applications

Szabó Magda, Ray Kroc és Brian Johnson. Egy sor neves születésnaposunk van. De van tőzsdei összefoglaló és lapszemle is, méghozzá Csók és könnyel! Állítólag befejezik az M0-st. Andó Gergellyel, a Közlekedésvilág lapcsoport lapigazgatójával beszélgettünk erről. Albérlő és bérbeadó minősítő-párosító oldalt fejlesztett egy csapat. Négyzetméter rovatunkban Danóczy Balázzsal, a rentingo.com alapítójával beszélgettünk. "Keresd a hazait!" rovatunkban Kiss Móni, az Equilor vezető elemzője számolta át a blue chipekre vonatkozó célárait.

GOOGLE "hip hop djcarl 2017" now! Spotify RapCaviar Playlist: 01. Logic f. Alessia Cara & Khalid – 1-800-273-8255 (V) 02. Wiz Khalifa f. Charlie Puth – See You Again 03. Santana f. The Product G&B – Maria Maria 04. DJ Khaled f. Rihanna & Bryson Tiller – Wild Thoughts 05. Rihanna – Desperado 06. Jay Z – The Story of O.J. 07. Eminem – Not Afraid (V) 08. Case – Missing You 09. SWV – Right Here-Human Nature 10. DJ Snake f. Justin Bieber – Let Me Love You (V) 11. French Montana f. Swae Lee – Unforgettable (V) 12. Dr. Dre f. Snoop Dogg – Still D.R.E. 13. Major Lazer f. DJ Snake f. M0 – Lean On 14. Calvin Harris f. Pharrell Williams, Katy Perry & Big Sean – Feels 15. Iggy Azalea f. Anitta – Switch 16. Alexa Ayaz f. Elephant Man – Hey Danze 17. Jay Z & Linkin Park – Numb/Encore (V) 18. Dej Loaf – No Fear 19. Neisha Neshae – White Sticks 20. T-Pain f. Young M.A. – F.B.G.M. 21. Mary J. Blige f. A$AP Rocky – Love Yourself 22. Meek Mill f. Chris Brown & Ty Dolla $ign – Whatever You Need 23. Lil Uzi Vert – XO Tour Llif3 24. Puff Daddy – I'll be Missing You Create an mp3 music DJ Carl© mix - http://bit.ly/2A5Fkkb (V)=Voiceover (S)=Shoutout (P)=Promo

GOOGLE "hip hop djcarl 2016" now! Spotify RapCaviar Playlist: 01. Spinz, Southside & Future – Commas 02. Rae Sremmurd f. Gucci Mane – Black Beatles 03. Twenty One Pilots – Heathens 04. Sia f. Kendrick Lamar – The Greatest 05. The Weeknd f. Daft Punk – Starboy 06. Usher f. Young Thug – No Limit 07. Nick Grant f. WatchTheDuck – Get Up 08. Gnash f. Olivia O'Brien – I Hate U, I Love U 09. DJ Snake f. Justin Bieber – Let Me Love You 10. Missy Elliott – Work It 11. Busta Rhymes – Put Your Hands Where My Eyes Could See 12. Meghan Trainor f. Yo Gotti – Better 13. Coldplay f. Beyonce – Hymn for the Weekend 14. Major Lazer f. Justin Bieber & M0 – Cold Water 15. Bruno Mars – 24K Magic 16. Ludacris f. Mystikal & I-20 – Move B_tch 17. Jay Z – Izzo 18. 50 Cent – In Da Club 19. Nicky Jam f. Kid Ink – With You Tonight 20. Justine Skye f. Wizkid – U Don't Know 21. Kiiara – Gold 22. DJ Khaled f. Nicki Minaj, Chris Brown, Future, August Alsina, Jeremih & Rick Ross – Do You Mind 23. Kap G – Girlfriend 24. A Boogie f. Fabolous – My Sh_t Create an mp3 music DJ Carl© mix - http://bit.ly/2A5Fkkb

GOOGLE "dance djcarl 2016" DJ Carl© Dance Music Playlist: 01. Me & My Toothbrush vs. Duke Dumont – Ocean Drive for Miles 02. Mike Perry f. Shy Martin – The Ocean 03. Lost Frequencies f. Sandro Cavazza – Beautiful Life 04. Mylo x Knife Party – Trending in your Arms 05. Sanjoy X Zoh – Slip Away 06. Tinashe – Superlove 07. Abel Ramos, Pendulum, Sebastian Ingrosso, Tommy Trash – Reload The Island Higher 08. Armand Van Helden – Wings 09. Major Lazer f. Justin Bieber & M0 – Cold Water 10. Clean Bandit f. Louisa Johnson – Tears 11. Arizona – I was Wrong 12. Jay Cosmic f. Happy Sometimes – Hero 13. Static Revenger – Happy People 14. Jonas Blue f. JP Cooper – Perfect Strangers 15. Jess Glynne – Don’t Be So Hard on Yourself 16. Coldplay – Adventure of a Lifetime 17. Mike Posner – I Took a Pill in Ibiza 18. Kungs vs. Cookin' on 3 Burners – This Girl 19. Moby – Natural Blues 20. Michael Calfan – Nobody Does It Better 21. Ferreck Dawn & Joe Stone – Sublime 22. DJ Snake f. Justin Bieber – Let Me Love You Create an mp3 music DJ Carl© mix - http://bit.ly/2A5Fkkb

GOOGLE "hip hop djcarl 2016" now! Spotify RapCaviar Playlist: 01. A Boogie Wit Da Hoodie – Sh*t 02. D.R.A.M. f. Lil Yachty – Broccoli 03. Dae Dae f. Lil Yachty – Wat U Mean 04. Frank Ocean – Novacane 05. T.I. f. Jay Z – Bring Em Out 06. Drake – Controlla 07. Diddy f. Nicole Scherzinger – Come to Me 08. Major Lazer f. Justin Bieber & M0 – Cold Water 09. Pitbull f. Flo Rida & LunchMoney Lewis – Greenlight 10. Kardinal Offishall f. Akon – Dangerous 11. Drake f. Rihanna – Too Good 12. Ludacris f. Mystikal & I-20 – Move B*tch 13. French Montana f. Drake – No Shopping 14. Lil Boosie f. Webbie & Foxx – Wipe Me Down 15. Juicy J f. A$AP Rocky – Scholarship 16. Calvin Harris f. Rihanna – This is What You Came For Create an mp3 music DJ Carl© mix - http://bit.ly/2A5Fkkb

GOOGLE "hip hop djcarl 2016" now! Spotify RapCaviar Playlist: 01. Kanye West & Jay Z f. Frank Ocean – Made in America 02. TOK – Footprints (When You Cry) 03. Geto Boys – The World is a Ghetto 04. Akon – Ghetto 05. Gang Starr – Code of the Streets 06. De La Soul – Stakes is High 07. KRS-One – MC's Act Like They Don't Know 08. Mobb Deep – Quiet Storm 09. Major Lazer & DJ Snake f. M0 & Ty Dolla Sign – Lean On 10. G-Eazy x Bebe Rexha – Me, Myself & I 11. DJ Khaled f. Drake – For Free 12. Ariana Grande – Into You 13. Fetty Wap – Wake Up 14. OutKast – Rosa Parks 15. DJ Mustard f. Nicki Minaj & Jeremih – Don't Hurt Me 16. Wale f. Sam Sneak – My P.Y.T. 17. Jay Z f. Timbaland – Open Letter Create an mp3 music DJ Carl© mix - http://bit.ly/2A5Fkkb

URL: http://djswa.com/Megamix by: DJ SwaYear: 2015IntroBad Blood - Tayloer Swift feat. Kendrick LamarThinking Out Loud - Ed SheeranHell Of A Night - Dustin LynchHey Mama - David Guetta feat Nicki Minaj & AfrojackKick The Dust Up - Luke BryanI Like Tuh - Carnage f. I Love MakonnenBad Girls - MKTOWet Dreamz - J. ColeI Need Your Love - Shaggy feat. MohombiEl perdón - Nicky Jam & Enrique IglesiasSee You Again - Wiz Khalifa feat. Charlie PuthLocked Away - R. City f. Adam LevineLove Me Like You Do - Ellie Goulding679 - Fetty Wap Feat. Remy BoyzThe Fix- Nelly F. JeremihDo It Again - Pia Mia feat. Chris Brown & TygaBlank Space - Taylor SwiftAll Hands On Deck - Tinashe f./Dej LoafLean On - Major Lazer Ft. Dj Snake & M0This Summer's Gonna Hurt - Maroon 5Cheyenne - Jason DeRuloLike I Can - Sam SmithWorth It - Fifth Harmony feat. Kid InkAbout The Money - T.I feat Jeezy, Young Thug & Lil WayneLevels - Nick JonasBitch Betta Have My Money - RihannaTruffle Butter - Nicki Minaj feat. DrakeDirty Work - Austin MahoneJello - Tina MinaPhotograph - Ed SheeranCant Feel My Face - The WeekndDowntown - Macklemore & Ryan LewisMarvin Gaye - Charlie Puth Feat. Meghan TrainorIt Takes Two (2015) - Rob Base & DJ EZ RockFun - Pitbull feat. Chris BrownWant To Want Me - Jason DeRuloUptown Funk - Mark Ronson Fe. Bruno MarsI Don't Like It, I Love It - Flo Rida feat Robin Thicke & Verdine WhiteAin’t Nobody (Loves Me Better) - Felix Jaehn Feat. Jasmine ThompsonCheerleader - OmiSugar - Maroon 5Milky Chance - Stolen DanceGhost Town - Adam LambertI Really Like You - Carly Rae JepsenHow Deep Is Your Love - Calvin Harris & DisciplesSugar - Robin Schulz f. Francesco YatesTime Of Our Lives - Pitbull & Ne-YoThe Party (This Is How We Do It) - Joe Stone feat. Montell Jordan+1 feat. Sam White - Martin SolveigFlux - Funkin MattDare Me (Stupidisco) (2k15 Remix) - Junior Jack feat. ShenaUMEK - An Estos (Original Mix)Higher Place - Dimitri Vegas & Like Mike feat. Ne-YoIntoxicated - Martin Solveig & GTAE Samba (2015K remix) - Junior JackBunnyDance - Oliver HeldensDominator - Peter Gelderblom, Randy Colle, MC GeeOh, Amazing Bass - Sander van DoornRenegade Mastah - Hi-LO3LAU & Nom De Strip feat. Estelle - The NightSultan + Shepard vs. Whitney Houston - It's Not Right, But It's OkayMetroda vs. Axwell - Watch The WoolitserThe Chemical Brothers - Hey Boy Hey Girl (2k15 Remix)Steve Angello, AN21 & Sebjak vs. Promise Land - GODS vs. Why I Still Love YouKwabs - WalkNicky Romero - SuperI'm An Albatraoz - AronChupaKensei - Ummet OzcanCharlie XCX - The RulesWaiting For Love - AviciiDimitri Vegas & Like Mike & Ummet Ozcan - The HumDavid Guetta & The Egg - Love Don't Let Me Go (2k15 remix)Tommy Trash feat. JHart - Wake The GiantSecrets - Tiesto & KSHMR feat. VassyFaithless - Insomnia 2.0 (2K15 remix)David Tort & Nick Marsh Feat. Crystal Waters – Let Me Be The OneMHATLP (HI-LO Edit) - Oliver Heldens & Da HoolManuel Galey, Luis Rondina & Flaremode - ItanimulliW&W & Headhunterz - We Control The SoundJordy Dazz, Merk & Kremont - Get Down The Disco NigthsDavid Guetta & Showtek feat. Magic! & Sonny Wilson - Sun Goes DownMobin Master vs. Trillogee feat. Carerra - WERK!Dyro vs. Alesso vs. Alvaro & Mercer - Welcome To Miami Bitchhttp://archive.org/download/DJSwaTheSwalibanYearmix2015/DJ%20Swa%20-%20The%20Swaliban%20Yearmix%202015.mp3

Reviews: Fantastic Four (2015) and Dragonball Z: Resurrection 'F' Trailer Spot: The Hateful Eight Opening and Closing Song: Lean On by Major Lazer & DJ Snake feat. M0

Tracklist mix du 01/15 : #AttrapeMoiSiTuPeux #1 Part.2 : 01 Mally Mall - Wake Up In It (Ft Tyga, Pusha T, French Montana & Sean Kingston) 02 The Kid Ryan - Run That 03 Tinashe - 2 On (Ft Schoolboy Q) 04 Tinashe - Little Things 05 Meek Mill - She Don't Know (Ft. Ty Dolla $ign) 06 Dj Mustard - Down On Me (Ft. Ty Dolla $ign & 2 Chainz) 07 Mase - Nothing (Ft Eric Bellinger) 08 Big Sean - I Don't Fuck With You (Ft E40) 09 Dj Mustard - 4 Digits (Ft. Fabolous & Eric Bellinger) 10 Mila J - Main Chick (Ft. Ty Dolla $ign) 11 Wonder Broz - Drop it (Ft. Sage The Gemini) 12 Jennifer Lopez - Girls (Ft Tyga) 13 Mishon - Conversation (Ft. Tyga) 14 Project Pat - Twerk It (Ft. Wiz Khalifa, Ty Dolla $ign & Wale) 15 Tyga - Hookah (Ft. Young Thug) 16 Iggy Azalea - Beg For It (Ft. M0) 17 Rick Ross - If They Knew (Ft. K. Michelle) 18 Fat Joe - Stressin (Ft. Jennifer Lopez) 19 Migos - Fight Night 20 Young Thug & Rich Homie Quan - Lifestyle

Introduction: Circulating tumor cells (CTCs) have been studied in breast cancer with the CellSearch® system. Given the low CTC counts in non-metastatic breast cancer, it is important to evaluate the inter-reader agreement. Methods: CellSearch® images (N = 272) of either CTCs or white blood cells or artifacts from 109 non-metastatic (M0) and 22 metastatic (M1) breast cancer patients from reported studies were sent to 22 readers from 15 academic laboratories and 8 readers from two Veridex laboratories. Each image was scored as No CTC vs CTC HER2-vs CTC HER2+. The 8 Veridex readers were summarized to a Veridex Consensus (VC) to compare each academic reader using % agreement and kappa (.) statistics. Agreement was compared according to disease stage and CTC counts using the Wilcoxon signed rank test. Results: For CTC definition (No CTC vs CTC), the median agreement between academic readers and VC was 92% (range 69 to 97%) with a median. of 0.83 (range 0.37 to 0.93). Lower agreement was observed in images from M0 (median 91%, range 70 to 96%) compared to M1 (median 98%, range 64 to 100%) patients (P < 0.001) and from M0 and < 3CTCs (median 87%, range 66 to 95%) compared to M0 and >= 3CTCs samples (median 95%, range 77 to 99%), (P < 0.001). For CTC HER2 expression (HER2-vs HER2+), the median agreement was 87% (range 51 to 95%) with a median. of 0.74 (range 0.25 to 0.90). Conclusions: The inter-reader agreement for CTC definition was high. Reduced agreement was observed in M0 patients with low CTC counts. Continuous training and independent image review are required.

Background: To report an unplanned interim analysis of a prospective, one-armed, single center phase I/II trial (NCT01566123). Methods: Between 2007 and 2013, 27 patients (pts) with primary/recurrent retroperitoneal sarcomas (size > 5 cm, M0, at least marginally resectable) were enrolled. The protocol attempted neoadjuvant IMRT using an integrated boost with doses of 45-50 Gy to PTV and 50-56 Gy to GTV in 25 fractions, followed by surgery and IOERT (10-12 Gy). Primary endpoint was 5-year-LC, secondary endpoints included PFS, OS, resectability, and acute/late toxicity. The majority of patients showed high grade lesions (FNCLCC G1:18%, G2:52%, G3:30%), predominantly liposarcomas (70%). Median tumor size was 15 cm (6-31). Results: Median follow-up was 33 months (5-75). Neoadjuvant IMRT was performed as planned (median dose 50 Gy, 26-55) in all except 2 pts (93%). Gross total resection was feasible in all except one patient. Final margin status was R0 in 6 (22%) and R1 in 20 pts (74%). Contiguous-organ resection was needed in all grossly resected patients. IOERT was performed in 23 pts (85%) with a median dose of 12 Gy (10-20 Gy). We observed 7 local recurrences, transferring into estimated 3- and 5-year-LC rates of 72%. Two were located outside the EBRT area and two were observed after more than 5 years. Locally recurrent situation had a significantly negative impact on local control. Distant failure was found in 8 pts, resulting in 3-and 5-year-DC rates of 63%. Patients with leiomyosarcoma had a significantly increased risk of distant failure. Estimated 3-and 5-year-rates were 40% for PFS and 74% for OS. Severe acute toxicity (grade 3) was present in 4 pts (15%). Severe postoperative complications were found in 9 pts (33%), of whom 2 finally died after multiple re-interventions. Severe late toxicity (grade 3) was scored in 6% of surviving patients after 1 year and none after 2 years. Conclusion: Combination of neoadjuvant IMRT, surgery and IOERT is feasible with acceptable toxicity and yields good results in terms of LC and OS in patients with high-risk retroperitoneal sarcomas. Long term follow-up seems mandatory given the observation of late recurrences. Accrual of patients will be continued with extended follow-up.

ESOW #70 - Ǫdade̱hnyóhaˀ (Fishing Dance) as sung by Gordie Buck. Song transferred from 'reel to reel' tape.

1. What Time is Love? (LP Mix) - The KLF 2. Make it Mine (v 1.0 Progress Mix) - The Shamen 3. Blue Eyed Pop (S1000 Mix) - The Sugarcubes 4. Love Baby - Fortran 5 5. Break 4 Love (Razormaid! Mix) - Raze 6. The Beginning (Roundabout Mix) - Seal 7. Walking Away (S.M.D. Mix) - Information Society 8. Don't Tell Me (Dance Remix) - Blancmange 9. Snappy (12" Remix) - Erasure 10. Beat of Life - Anything Box 11. Je T'aime (Extended Mix) - Vicious Pink 12. Bitter Heart (Razormaid! Mix) - Seona Dancing 13. Regret (The Fire Island Mix) - New Order 14. So Weit Wie Noch Nie (Erlend Oye Mix) - Jurgen Paape 15. The Caterpillar (Flicker Mix) - The Cure   Notes and Other Random Things:  Happy Memorial Day Weekend to all my US listeners and happy regular weekend to everyone else around the globe. The occasion here in the states marks a time of sun, friends, family, icy beverages and plumes of smoke wafting from the grills and barbeque pits of backyards everywhere. But it also marks a time of quiet reflection and giving thanks to the men and women in the Armed Forces who have served our country and have, in some cases, given their lives to protect our shores. It is thanks to their bravery and their willingness to put everything on the line that the rest of us have the freedom to over-eat, get sloppy drunk and moon my television while screaming obscenities at whichever NASCAR event happens to be on. Oh, don't tell me you haven't done it. Anyway, even though it doesn't seem like nearly enough, a heartfelt "Thank You" to all those in uniform. Heroes - all of you. On such a patriotic day for us in the states, and with my being one of its inhabitants, I almost feel guilty including songs with foreign lyrics like Vicious Pink's French-inspired Je T'aime and Jurgen Paape's So Weit Wie Noch Nie. The latter song includes samples from an artist named Daliah Lavi, whose lyric appears in a 1972 track called Vielleicht Schon Morgen. Mind you, I have nothing against the French and the Germans. One makes great fries and the other exceptional gummy bears. It's just that on a day like today, I somehow feel like the whole podcast should be nothing but John Philip Sousa samples sprinkled into a mash-up of The National Anthem and Take Me Out to the Ball Game, you know? But because none of those are 80s tunes (or 90s tunes for that matter) that would never happen. Of course, considering that this podcast sort of strayed from a typically unwavering adherence to the 80s & 90s theme anyway, I suppose I could have chosen that path. For instance, the Jurgen Paape track is actually a 2002 release. It just fit so well with New Order's Regret that I couldn't resist. Also, astute listeners will hear an MC5 sample right at the beginning of the KLF track What Time is Love? Yeah, that's lead singer Rob Tyner screaming, "Kick out the jams, M0+#er Fu(k=r!" And if you listen closely and know well your old people music, you will hear a number of other samples including a highly recognizable "1 ... 2 ... 3 ...4" from the Beatles in the remix of Make it Mine by The Shamen; and "It is time ..." a chopped up sample from Chrissy Hynde of The Pretenders in the track Love Baby by Fortran 5. The original lyric appeared in the song Stop Your Sobbing. Back to the KLF … James Cauty and William Drummond have appeared in an earlier episode of CRC. At that time, I mentioned how musically irreverent they were and how glaringly insubordinate they were to the music industry as a whole. It seemed as if everything they did was merely to get a reaction out of the public or to challenge the accepted definitions of art. One read of their hilarious and very tongue-in-cheek book How to Have a Number One the Easy Way will support that notion, but it doesn’t mean they didn’t pen some very infectious and highly danceable tracks in the process. What Time is Love?, despite dripping with mid-range frequencies, is one of them. Now, pay attention because here are some names that you should know as they helped make the song what it is: Isaac Bello: he’s the guy who does the rapping in the song. Wanda Dee: she’s responsible for the “I wanna see you sweat” lyric And then there are P.P. Arnold and Katie Kisson, who yell “Mu Mu!” at various intervals. How’s that for a resume builder? The Sugarcubes make their second appearance on CRC with the excellent remix of Blue Eyed Pop. As most Bjork fans know, the Icelandic collective is where the pint-sized pop star first gained international acclaim, though she had been involved in music from a very young age, even recording her first album at age 11. She has also had a brilliant solo career and contributed vocals to the song QMart on the 808 State album Ex:el. This mix of Blue Eyed Pop was done by S1000. The DJ/production duo consisted of Mike Koglin and Spencer Williams. Koglin has gone on to become a very prominent trance DJ and producer these days, running his own record imprint called Noys Music. To those younger listeners with a larger familiarity with the trance scene, he had a huge club hit in 1998 with a track called The Silence, which was a reworking of Depeche Mode’s Enjoy the Silence.  Raze were conceived by American producer Vaughn Mason with singer Keith Thompson contributing vocals. Though Break 4 Love was released in 1988, Thompson also did the vocal honors on a track called Jack the Groove in 1986. That song was one of the very first house music chart topping tracks in the UK, creeping into the top 20 at one point. The Pet Shop Boys and Peter Rauhofer, who also performed under the name Club 69, did a cover of Break 4 Love in 2001. Using the name The Collaboration, the track appears on the bonus disc of the album Release and as a b-side to the second disc of their single Home and Dry. The Razormaid! version here is pretty filthy at points, thus the Explicit tag on this podcast. It’s a pretty muddy, steamy affair anyway, but some of the samples might make you squirm a bit if you’re within earshot of your parents while listening. Why on earth you would put yourself into that predicament anyway is beyond me. Then again, as the guy who just admitted he moons his television, I probably don't have much room to judge. You probably don’t want to play this one around your kids either, unless you’re prepared to answer a LOT of questions. Information Society have appeared on CRC several times in the past and they will appear again in the future. I’ll let the band themselves tell you about this particular track. I’m still trying to figure out what S.M.D. stands for. “This was the 2nd single released off the ‘first’ album. It did almost as well as What's On Your Mind, getting to #9 in the top 40 in the fall of '88. The video got a lot of MTV airplay. We had a big problem with this one in the studio. When we were mixing, and we got to the vocals, they sounded distorted in a very strange manner. Of course, the first thing we did was to solo the vocals to hear what was wrong with them. Then we couldn't hear anything wrong with them, so we shook our heads and went back to mixing. Then they sounded distorted again. Only WITH the tracks did they sound distorted. Eventually we realised that the super-heavy TR-808 kick drum sound was creating the ILLUSION of distortion in the vocals, similar to the effect of talking into a fan. We had to remove the super-sub-kick during the vocals sections.” They went on to say, “It was on this single that we began to realise how little control a band, especially a dance band, really has over its re-mixes. We rejected the Shep Pettibone mix outright. It went on the CD anyway. We really didn't like the "The Space Age" samples in the Space Age mix, they stayed.” Hmmmm. I think I’m getting some pretty good ideas about what the S, M, and the D might stand for now! Erasure are no stranger to this podcast nor will they ever be with the sheer volume of catchy dance tracks Andy Bell and Vince Clarke have cobbled together over the twenty-plus years they have been together. Snappy is the b-side to the song Chorus, which appeared on the album of the same name. This 12” mix was produced by uber-producer extraordinaire Martyn Phillips. Fans of Erasure (and Depeche Mode for that matter) might be interested to know that an album collaboration between Vince Clarke (an original member of DM) and Martin Gore is forthcoming. On August 27th of last year, Clark shared via Twitter that he and Gore had recorded a track called “Zaat”, which was to appear on the next Erasure album. The two apparently had enough creative energy together to crank out a full-length. As far as I know, no dates have been set for either release at this point. Last, but not least, I wanted to write a few words about Seona Dancing (pronounced like Shawna). The knowledge has gained a bit of traction with the success of The Office in the UK and all his other pursuits, but Seona Dancing was the musical outlet for one Ricky Gervais when he was but a skinny little gothy/new wavy-looking kid back in the day. They had two single releases: this song and one called More to Lose, but after both achieved only modest (and apparently unofficial) chart positioning, he and friend/bandmate Bill Macrae decided to call it a day in 1984. Gervais is certainly not regretting that move, though any lovers of 80s electronica might beg to differ. As a side note, if you have small kids, do yourself a favor and don't let them listen to Break 4 Love. Did I already say that? In all seriousness though, get Ricky's excellent Flanimals series of children’s books. I happened to pick up the first one a few days ago and it’s really quite funny. It’s a brief biography of a bunch of non-sensical creatures with non-sensical names along with descriptions of their habits and behavioral traits. It’s a very entertaining read, I must admit. I also must admit I think I bought it more for myself than for anyone else. Hey, I do an 80s podcast. What kind of maturity level do you think you’re dealing with here? Thanks to everyone for listening. I hope to be back again soon with another episode. In the meantime, enjoy this one and be sure to support the artists you like. Without their efforts, none of this is possible.   

Objectives: It was the aim of this study to assess our institutional experience with definitive chemoradiation (CRT) versus induction chemotherapy followed by CRT with or without surgery (C-CRT/S) in esophageal cancer. Methods: We retrospectively analyzed 129 institutional patients with locally advanced esophageal cancer who had been treated by either CRT in analogy to the RTOG 8501 trial (n = 78) or C-CRT/S (n = 51). Results: The median, 2-and 5-year overall survival (OS) of the entire collective was 17.6 months, 42 and 24%, respectively, without a significant difference between the CRT and C-CRT/S groups. In C-CRT/S patients, surgery statistically improved the locoregional control (LRC) rates (2-year LRC 73.6 vs. 21.2%; p = 0.003); however, this was translated only into a trend towards improved OS (p = 0.084). The impact of escalated radiation doses (>= 60.0 vs.

Background: As cell-free circulating DNA exists predominantly as mono-and oligonucleosomes, the focus of the current study was to examine the interplay of circulating nucleosomes, DNA, proteases and caspases in blood of patients with benign and malignant breast diseases. Methods: The concentrations of cell-free DNA and nucleosomes as well as the protease and caspase activities were measured in serum of patients with benign breast disease (n = 20), primary breast cancer (M0, n = 31), metastatic breast cancer (M1, n = 32), and healthy individuals (n = 28) by PicoGreen, Cell Death Detection ELISA, Protease Fluorescent Detection Kit and Caspase-Glo (R) 3/7 Assay, respectively. Results: Patients with benign and malignant tumors had significantly higher levels of circulating nucleic acids in their blood than healthy individuals (p = 0.001, p = 0.0001), whereas these levels could not discriminate between benign and malignant lesions. Our analyses of all serum samples revealed significant correlations of circulating nucleosome with DNA concentrations (p = 0.001), nucleosome concentrations with caspase activities (p = 0.008), and caspase with protease activities (p = 0.0001). High serum levels of protease and caspase activities associated with advanced tumor stages (p = 0.009). Patients with lymph node-positive breast cancer had significantly higher nucleosome levels in their blood than node-negative patients (p = 0.004). The presence of distant metastases associated with a significant increase in serum nucleosome (p = 0.01) and DNA levels (p = 0.04), and protease activities (p = 0.008). Conclusion: Our findings demonstrate that high circulating nucleic acid concentrations in blood are no indicators of a malignant breast tumor. However, the observed changes in apoptosis-related deregulation of proteolytic activities along with the elevated serum levels of nucleosomes and DNA in blood are linked to breast cancer progression.

Introduction: MicroRNAs (miRs) are interesting new diagnostic targets that may provide important insights into the molecular pathogenesis of breast cancer. Here we evaluated, for the first time, the feasibility and clinical utility of circulating miRs as biomarkers for the detection and staging of breast cancer. Methods: The relative concentrations of breast cancer-associated miR10b, miR34a, miR141 and miR155 were measured in the blood serum of 89 patients with primary breast cancer (M0, n = 59) and metastatic disease (M1, n = 30), and 29 healthy women by a TaqMan MicroRNA Assay. Results: The relative concentrations of total RNA (P = 0.0001) and miR155 (P = 0.0001) in serum significantly discriminated M0-patients from healthy women, whereas miR10b (P = 0.005), miR34a (P = 0.001) and miR155 (P = 0.008) discriminated M1-patients from healthy controls. In breast cancer patients, the changes in the levels of total RNA (P = 0.0001), miR10b (P = 0.01), miR34a (P = 0.003) and miR155 (P = 0.002) correlated with the presence of overt metastases. Within the M0-cohort, patients at advanced tumor stages (pT3 to 4) had significantly more total RNA (P = 0.0001) and miR34a (P = 0.01) in their blood than patients at early tumor stages (pT1 to 2). Conclusions: This pilot study provides first evidence that tumor-associated circulating miRs are elevated in the blood of breast cancer patients and associated with tumor progression.

Purpose: Ileal carcinoids are gut epithelial tumors originating from serotonin-containing enterochromaffin (EC) cells. Therapeutic options for effectively inhibiting the growth and spread of metastatic carcinoids are still limited. We aimed to identify the role of matrix metalloproteinases (MMPs) and their endogenous tissue inhibitors (TIMPs) during tumor development and metastasis. Patients and Methods: Tissue samples were obtained from surgically treated patients. Expression of the EC-cell marker, vesicular monoamine transporter-1 (VMAT-1), was used to verify ileal carcinoids. We investigated the differential expression of MMP-2, 7, 9, 11, and 13 and their endogenous inhibitors (TIMP-1, 2, and 3) by quantitative real-time RT-PCR in 25 primary tumors, their corresponding lymph node metastases and/or liver metastases and matched normal mucosa. Results: Significantly increased expression of VMAT-1, MMP-2, MMP-11, TIMP-1 and TIMP-3 was determined by quantitative RT-PCR in EC-cell carcinoids compared to normal intestinal mucosa (p < 0.05). In contrast, MMP-2 and MMP-9 as well as TIMP-1, TIMP-2, and TIMP-3 expression in primary tumors of patients with liver metastases (M1) was significantly lower than in patients lacking liver metastases (M0). EC-cell tumors were significantly larger in the M1 group of tumors, while VMAT-1 expression was significantly decreased. We found an inverse correlation between tumor size and prognosis. Univariate analysis further revealed that decreased expression of VMAT-1, MMP-2 and TIMP-3 in primary tumors was significantly associated with a reduced survival time of the patients. Conclusion: Our data reveal that MMP-2 and TIMP-3 expression together with VMAT-1 expression are of potential prognostic and clinical value in ileal carcinoids. Copyright (C) 2008 S. Karger AG, Basel

Background: Membrane-bound heat shock protein 70 (Hsp70) serves as a tumor-specific recognition structure for Hsp70-peptide (TKD) plus IL-2 activated NK cells. A phase I clinical trial has shown that repeated re-infusions of ex vivo TKD/IL-2-activated, autologous leukapheresis product is safe. This study investigated the maintenance of the cytolytic activity of NK cells against K562 cells and autologous tumor after 6 plus 3 infusions of TKD/IL-2-activated effector cells. Methods: A stable tumor cell line was generated from the resected anastomotic relapse of a patient with colon carcinoma (pT3, N2, M0, G2). Two months after surgery, the patient received the first monthly i.v. infusion of his ex vivo TKD/IL-2-activated peripheral blood mononuclear cells (PBMNC). After 6 infusions and a pause of 3 months, the patient received another 3 cell infusions. The phenotypic characteristics and activation status of tumor and effector cells were determined immediately before and at times after each infusion. Results: The NK cell ligands Hsp70, MICA/B, and ULBP-1,2,3 were expressed on the patient's anastomotic relapse. An increased density of activatory NK cell receptors following ex vivo stimulation correlated with an enhanced anti-tumoricidal activity. After 4 re-infusion cycles, the intrinsic cytolytic activity of non-stimulated PBMNC was significantly elevated and this heightened responsiveness persisted for up to 3 months after the last infusion. Another 2 re-stimulations with TKD/IL-2 restored the cytolytic activity after the therapeutic pause. Conclusion: In a patient with colon carcinoma, repeated infusions of ex vivo TKD/IL-2-activated PBMNC initiate an intrinsic NK cell-mediated cytolytic activity against autologous tumor cells.

Bei der akuten myeloischen Leukämie (AML) stellen die unkontrollierte Proliferation und Reifungsblockade myeloider Vorläuferzellen, Expansion dieser Zellen in das periphere Blut, extramedulläre Manifestationen und verminderte Elimination der Leukämiezellen durch das Immunsystem grundlegende Pathomechanismen dar. Diese Vorgänge werden über ein komplexes Zusammenspiel von Zytokinen und Adhäsionsmolekülen reguliert. In dieser Arbeit wurde daher mittels Durchflußzytometrie die Expression von Zytokinrezeptoren, Adhäsions- und kostimulatorischen Molekülen in Knochenmarks(KM-) Proben von 103 AML-Patienten bei Diagnosestellung und acht gesunden Probanden untersucht. Zytokinrezeptoren weisen bei der normalen Hämopoese ein reifegradabhängiges und linienspezifisches Expressionsmuster auf. Es wurden daher zum einen Zytokinrezeptoren ausgewählt, die schon in der frühen Hämopoese exprimiert werden, wie der SCF-R (CD117), FL-R (CD135), IL-3-R (CD123) und zum andern Zytokinrezeptoren, die erst in späteren Differenzierungsstadien der monozytären Zelllinie (v.a. GM-CSF-R; CD116) und der granulozytären Zelllinie (v.a. G-CSF-R, CD114) exprimiert werden. Die gp130-Subunit (CD130) stellt die signaltransduzierende Untereinheit von IL-6, IL-11, LIF etc. dar und wirkt synergistisch auf allen Stufen der Hämopoese mit. Die untersuchten Adhäsionsmoleküle wurden in drei Gruppen unterteilt: a) Adhäsionsmoleküle, die den Kontakt zur KM-Matrix oder zu sich selbst beeinflussen: VLA-2 (CD49b), VLA-3 (CD49c) und die erst kürzlich auf hämopoetischen Zellen gefundenen Adhäsionsmoleküle PRR-1 und PRR-2. b) Adhäsionsmoleküle, die den Kontakt zum Endothel fördern: LFA-1 (CD11a), Mac-1 (CD11b), L-Selektin (CD62L) und UPA-R (CD87) c) kostimulatorische Moleküle, die eine Rolle bei der Interaktion der Leukämiezellen mit immunkompetenten Zellen spielen: ICAM-1 (CD54), LFA-3 (CD58), B7-1 (CD80), B7-2 (CD87) und NCAM (CD58). Eine KM-Probe wurde als positiv gewertet, wenn mehr als 20% der Blasten im Auswertefenster den entsprechenden Marker exprimierten. Ergebnisse: Der durchschnittliche Anteil Zytokinrezeptoren exprimierender Zellen war in KM-Proben von AML-Patienten deutlich höher als in KM-Proben von gesunden Probanden. Einzige Ausnahme bildete die gp130-Subunit, die nur auf durchschnittlich 4% der AML-Blasten exprimiert wurde, während durchschnittlich 23% der Zellen in gesunden KM-Proben die gp130-Subunit exprimierten. Bei den Adhäsionsmolekülen zeigte sich im Vergleich zu den gesunden KM-Proben bei der AML ein höherer Anteil von Zellen, die kostimulatorische und Endothel-Kontakt-fördernde Moleküle exprimierten, während der Anteil von Zellen, die das Stroma-Kontakt-fördernde ß1-Integrin VLA-2 exprimierten, vermindert war. VLA-3 konnte dagegen in keinem der untersuchten AML-Fälle und der gesunden KM-Proben als positiv gewertet werden. Innerhalb der AML-Subtypen konnte ein reifegrad– und linienabhängiges (monozytäres, granulozytäres) Verteilungsmuster der Zytokinrezeptoren festgestellt werden: Blasten unreifer Leukämien (M0; M1) exprimierten bevorzugt SCF-R und FL-R. Blasten von AML-Subtypen, die der granulozytären Differenzierungslinie zugeordnet werden (M2, M3), exprimierten v.a. G-CSF-R. Blasten monozytärer Leukämien (M4, M5) exprimierten v.a. GM-CSF-R und FL-R. Der IL-3-R wurde in fast allen AML-KM-Proben auf einem Großteil der Blasten exprimiert. Den größten Anteil positiver Zellen für Adhäsions- und kostimulatorische Moleküle (Integrine, B7-2, NCAM, UPA-R) wiesen die monozytären Leukämien auf. B7-1 wurde v.a. auf Blasten des FAB-Typs M3 exprimiert. L-Selektin, ICAM-1 und PRR-1/PRR-2 zeigten eine variable Expression innerhalb aller FAB-Typen. In der Gruppe der sekundären Leukämien waren signifikant mehr Fälle Mac-1-positiv als in der Gruppe der primären Leukämien (p = 0.074, Qui2-Test). Ansonsten zeigten sich zwischen primären und sekundären Leukämien keine signifikanten Unterschiede. Wichtig für die Entscheidung über Art und Intensität der Therapie bei der AML ist das Abschätzen der Prognose eines Patienten bei Diagnosestellung. Bislang werden Patienten v.a. anhand zytogenetischer Untersuchungen von Karyotypanomalien in Prognosegruppen eingeteilt. Da aber nur ca. 50-60% der AML-Patienten chromosomale Veränderungen aufweisen, besteht ein Bedarf an Karyotyp-unabhängigen Prognosekriterien. Zytogenetische Analysen wurden bei allen AML-KM-Proben durchgeführt und die Expression der Marker sowohl mit den zytogenetischen Risikogruppen als auch mit dem tatsächlichen klinischen Verlauf der Patienten korreliert. In die klinische Auswertung wurden nur Patienten (n = 55) eingeschlossen, die nach dem Therapieprotokoll der German AML-Cooperative-Group behandelt worden waren. In der zytogenetisch günstigen Prognosegruppe zeigten sich im Vergleich zur zytogenetisch ungünstigen Prognosegruppe signifikant mehr G-CSF-R-positive Zellen (p = 0.027, T-Test), signifikant weniger L-Selektin-positive Fälle (p = 0.037, Qui2-Test) und signifikant mehr Mac-1- und PRR-1-positive Fälle (p = 0.005; p = 0.009; Qui2-Test). Diese Marker zeigten aber keine signifikanten Unterschiede bezüglich Remissionrate und progressfreier Überlebenswahrscheinlichkeit der Patienten. Dies läßt sich auf die zum Teil geringe Fallzahl und die kurze Beobachtungsdauer von im Mittel 11 Monaten nach Remission erklären. Andere Marker zeigten dagegen keine Korrelation mit den zytogenetischen Risikogruppen, dagegen aber mit dem tatsächlichen klinischen Verlauf der Patienten: VLA-2-, NCAM-, UPA-R-positive Leukämien zeigten eine signifikant niedrigere Remissionsrate (p = 0.049, p = 0.03, p = 0.03, Qui2-Test). Patienten, in deren KM-Proben >85% der Blasten den FL-R oder >45,5% den SCF-R exprimierten, wiesen eine signifikant niedrigere Wahrscheinlichkeit für progressfreies Überleben auf, ebenso wie Patienten, in deren KM-Proben >60,5% der Blasten ICAM-1-, >15% B7-1-, >65% B7-2- und >8% NCAM-positiv waren. NCAM korrelierte als einziger Marker negativ sowohl mit der Remissionsrate, als auch mit der progressfreien Überlebenswahrscheinlichkeit, allerdings nicht mit der Einteilung in zytogenetische Risikogruppen. Auch für die übrigen Marker konnten Cut-off-Werte für den Anteil Marker-positiver Blasten ermittelt werden, bei denen aus dem Vergleich der entstandenen Gruppen ein deutlicher Unterschied in der Dauer der progressfreien Überlebenszeit hervorging. Diese Unterschiede waren allerdings aufgrund der geringen Fallzahl nicht signifikant, so dass sich eine eindeutige prognostische Aussagen nicht treffen ließ. Dabei wiesen Patienten mit einem höheren Anteil von G-CSF-R-, GM-CSF-R- und einem niedrigeren Anteil von IL-3-R-exprimierenden Blasten eine längere progressfreie Überlebenszeit auf. Patienten mit sehr hohem Anteil PRR-2- oder mit geringem Anteil PRR-1-positiver Blasten tendierten zu einer eher kürzeren progressfreien Überlebenszeit. Umgekehrt wies eine niedrige Expression von Endothel-Kontakt fördernden Oberflächenmolekülen, wie z.B. L-Selektin, Mac-1 und UPA-R auf eine schlechte Prognose hinsichtlich der Dauer des progressfreien Überlebens hin. Therapeutische Konsequenzen: Die in dieser Arbeit aufgezeigten Zusammenhänge zwischen der Expression bestimmter Oberflächenmarker und dem klinischen Verlauf der Patienten helfen, die Prognoseeinschätzung von Patienten - über die Zytogenetik hinaus - weiter zu spezifizieren: So stellt die NCAM-positive Leukämie eine eigene Entität mit prognostisch schlechtem Verlauf unabhängig vom Karyotyp dar. Bei UPA-R- und/oder VLA-2-positiven AML-Fällen sollten aufgrund der verminderten Remissionswahrscheinlichkeit intensivere therapeutische Induktionstherapien eingeleitet werden. Für die Remissionsdauer ist sowohl die hohe Expression kostimulatorischer Moleküle, als auch die hohe Expression von Zytokinrezeptoren, die v.a. auf Stammzellebene wirksam sind und die die Expression von diesen kostimulatorischen Molekülen fördern, prognostisch ungünstig. Diese Patienten sollten bei intensiver Konsolidierungstherapie engmaschig kontrolliert werden und die Indikation zur Knochenmarkstransplantation sollte frühzeitig gestellt weren. In der Zytokintherapie werden G-CSF und GM-CSF regelmäßig in der Klinik zur Verkürzung der Neutropeniephase nach Chemotherapie eingesetzt. Dagegen konnte mit dem Einsatz von G-CSF und GM-CSF als Priming-Medikamente bisher noch kein eindeutiger klinischer Benefit für die Patienten erzielt werden. Die in dieser Arbeit vorgestellten Ergebnisse einer linienspezifischen und reifegradabhängigen Expression der Zytokinrezeptoren legen nahe, dass G-CSF als Primingmedikament v.a. bei granulozytär-differenzierten AML-Subtypen und GM-CSF eher bei monozytär-differenzierten AML-Subtypen eingesetzt werden sollte. In der Supportivtherapie, bei der die Stimulation von AML-Blasten nicht mehr gewünscht ist, sollten G- und GM-CSF genau umgekehrt eingesetzt werden. Da eine hohe Expression von FL-R und SCF-R mit einer schlechten Prognose für die Dauer des progressfreien Überlebens korrelierte, kann sich eine Stimulation dieser Rezeptoren durch die Gabe von SCF und FL in der Supportivtherapie eher ungünstig auswirken, ebenso wie beim Priming, da auch gesunde Stammzellen stimuliert und damit sensibler gegen Zytostatika werden. Darüber hinaus geben diese Ergebnisse auch Hinweise auf mögliche pathobiologische Bedeutungen und damit verbundener neuer therapeutischer Strategien bei der AML: So kann die erhöhte FL-R-Expression - wie bei der Tandemduplikation des FL-R auch - zu einer erhöhten, prognostisch ungünstigen Phophorylierung von Tyrosinkinasen führen. Auch der SCF-R aktiviert intrazellulär Tyrosinkinasen. Neue Medikamente, wie z.B. Tyrosinkinase-Inhibitoren, oder Dexamethason, das die FL-R-Expression auf den AML-Blasten herunterreguliert, könnten bei diesen AML-Patienten neue benefit-bringende therapeutische Möglichkeiten darstellen. Ebenso scheint die Immunantwort bei AML-Patienten trotz, oder vielleicht sogar gerade bei Expression von kostimulatorischen Molekülen vermindert zu sein, was die Gabe von immunstimulierenden Medikamenten, wie rIL-2 oder CTLA-4-Inhibitoren im Bereich der Immuntherapie sinnvoll erscheinen lässt. So leistet diese Arbeit nicht nur einen Beitrag zur Diagnostik, Prognose und Biologie der AML, sondern entwickelt in Zusammenschau mit bereits publizierten Daten neue, therapeutische Möglichkeiten für die Behandlung der AML.